The present invention relates to a medical apparatus for extracorporeal treatment of blood. The present invention also relates to a process of calculating set flow rates in a medical apparatus for extracorporeal fluid processing.
In more detail, the present invention is applicable in the context of continuous renal replacement therapies (CRRT) with or without anticoagulation, for example CRRT with or without systemic anticoagulation (e.g., heparin)/with or without regional anticoagulation (e.g., citrate). In particular, the present invention may be advantageously used for administering regional citrate anticoagulation (RCA) during continuous renal replacement therapies (CRRT).
The kidneys fulfil many functions, including the removal of water, the excretion of catabolites (or waste from the metabolism, for example urea and creatinine), the regulation of the concentration of the electrolytes in the blood (e.g. sodium, potassium, magnesium, calcium, bicarbonates, phosphates, chlorides) and the regulation of the acid/base equilibrium within the body, which is obtained in particular by the removal of weak acids and by the production of ammonium salts. In individuals who have lost (temporarily or permanently) the use of their kidneys, since these excretion and regulation mechanisms no longer work, the body accumulates water and waste from the metabolism and exhibits an excess of electrolytes, as well as, in general, acidosis, the pH of the blood plasma shifting downwards, below 7.35 (the blood pH normally varies within narrow limits of between 7.35 and 7.45). As mentioned, in order to overcome renal dysfunction, resort is conventionally made to a blood treatment involving extracorporeal circulation through an exchanger having a semipermeable membrane (dialyzer) in which the patients blood is circulated on one side of the membrane and a dialysis liquid, comprising the main electrolytes of the blood in concentrations close to those in the blood of a healthy subject, is circulated on the other side. Furthermore, a pressure difference is created between the two compartments of the dialyzer which are delimited by the semipermeable membrane, so that a fraction of the plasma fluid passes by ultrafiltration through the membrane into the compartment containing the dialysis liquid. The blood treatment which takes place in a dialyzer as regards waste from the metabolism and electrolytes results from two mechanisms of molecular transport through the membrane. On the one hand, the molecules migrate from the liquid where their concentration is higher to the liquid where their concentration is lower. This is diffusive transport. On the other hand, certain catabolites and certain electrolytes are entrained by the plasma fluid which filters through the membrane under the effect of the pressure difference created between the two compartments of the exchanger. This is convective transport. Three of the abovementioned functions of the kidney, namely the removal of water, the excretion of catabolites and the regulation of the electrolytic concentration of the blood, are therefore performed in a conventional blood treatment device by the combination of dialysis and blood filtration (this combination is referred to as hemodiafiltration). To perform one or more of the above described treatments, extracorporeal blood treatment equipment may comprise a plurality of lines for delivering fluid directly to the patient or into the extracorporeal blood circuit.
When setting up the machine, an operator usually imposes the blood pump flow rate, the individual flow rates for each of the infusion lines, the flow rate for the dialysis line and for the effluent line (in reality this latter may alternatively be calculated based on the set patient fluid removal rate). The set values for the flow rates on each line we used to control respective pumps: in other words, a plurality of pumps are used where each pump draws fluid from or supplies fluid to a respective fluid container according to the set flow rate value for the respective line. Setting up of the machine is therefore cumbersome as it entails the definition and entry on the part of the operator of a relatively high number of flow rates. Moreover, the independent setting of each one of the flow rates does not provide the operator with intuitive information in terms of medically relevant prescription parameters. Finally, the need for independently setting a plurality of parameters may be source of errors and does not allow to optimize fluid consumption.
WO 2013/030642 deals with a blood treatment apparatus and a process of setting up a medical apparatus for the delivery or collection of fluids, wherein a control unit is configured calculate set values of two or more of the fluid flow rates based on a fluid flow rate set by the operator and on a prescribed dose value. However, WO 2013/030642 does not focus on the acid-base balance management aspects and does not specifically address the issue of acid base balance in regional anticoagulation in the context of CRRT.
As regards the regulation of the acid/base equilibrium inside the body, the approach adopted to overcome renal deficiency is to act on a mechanism by which the acid/base equilibrium inside the body is regulated, this mechanism consisting of the buffer systems of the blood, the main one of which comprises carbonic acid, as a weak acid, associated with its alkali salt, bicarbonate. This is why, in order to correct acidosis in a patient suffering from renal insufficiency, he/she is administered with bicarbonate via the vascular route, directly or indirectly, during a hemodialysis session. In the field of renal treatment, continuous renal replacement therapy (CRRT) has been widely used in critically ill patients with acute kidney injury and anticoagulation of the extracorporeal blood is necessary to maintain the patency of the circuit. In recent decades, different anticoagulation strategies have been used in clinical settings and heparin is the most commonly used anticoagulant. Although heparin has the advantages of low cost, easy monitoring and simple reversal, it may increase bleeding. Additionally, there is the risk of heparin-induced thrombocytopenia type II that can result in life-threatening complications. Regional citrate anticoagulation (RCA), which was first introduced into clinical use in the early 1980s, has been recommended as the most suitable form of CRRT regional circuit anticoagulation and has been safely used even in patients with severe liver dysfunction. However, citrate infusion in critically ill patients impacts a variety of metabolic systems, which can lead to metabolic alkalosis, hypocalcaemia and citrate excessive load/toxicity. These potential disturbances may be partially resolved by careful monitoring, adherence to treatment protocols, and oversight by trained staff in clinical practice. Notwithstanding the above criticalities, citrate anticoagulation has become the preferred anticoagulation choice for continuous renal replacement therapies (CRRT) as minimizing patient bleeding risks (regional anticoagulation effect) and increasing extracorporeal blood circuit life time. While RCA has some limitations with respect to compatibility with ‘large’ blood flow rates, this is not a problem in CRRT where efficiency is primarily driven by the fluid exchange rate and where the vast majority of treatments are delivered at blood flow rate below 200 ml/min. Fast metabolism of the citrate infused to the patient is part of the key mechanisms making RCA successful. Citrate metabolism produces energy, as well as bicarbonate and CO2 while releasing conplexed calcium. In the situation where large amounts of citrate are infused to the patient, large amounts of bicarbonate are produced, up to the point where metabolic alkalosis is generated. Citrate accumulation matches with the scenario where systemic citrate concentration is significantly increased. It can develop in two circumstances ‘normal’ citrate load combined to poor citrate metabolism, and ‘normal’ citrate metabolism combined to large citrate load. The first scenario is likely to lead to metabolic acidosis due to a low production rate of bicarbonate from citrate. The second scenario is considered and addressed in the present application, specifically in respect to CRRT therapies in the RCA context. Consequence of citrate accumulation is a need to increase total calcium concentration as to keep (systemic) ionised calcium within the physiological range. This can be achieved by increasing the calcium infusion rate. This problem is a transitory problem during initiation of the therapy, as a safe steady state can be reached after stabilization of systemic citrate concentration (6-8 hours). Discontinuation of the therapy may however lead to an episode of hypercalcemia (as citrate is metabolized and complex-bound calcium is released). In the clinical setting, citrate accumulation is diagnosed via the monitoring of total to ionised systemic calcium ratio (ratio>2.5 indicating probable citrate accumulation). Further, once citrate enters the patient systemic circulation, it is metabolized to bicarbonate on a 1:3 basis; thus, 1 mmol citrate yields 3 mmol bicarbonate. In presence of high citrate load, large amounts of bicarbonate are produced with the risk of metabolic alkalosis. Therefore, though regional anticoagulation may highly alleviate the adverse effects of heparin, RCA imposes the need of proper monitoring the acid-base balance in the patient blood, to avoid severe risks of alkalosis.
EP0678301 relates to an artificial kidney for intensive care particularly adapted to treating people suffering temporarily from kidney failure following an accident or a surgical operation. As clarified in the prior art document, in addition to purifying plasma wastes (e.g. urea) and to remove excess water, the kidneys play an important role in maintaining the acid-base equilibrium of the blood. Since the final concentration of bicarbonate in the blood depends on the concentration of bicarbonate in the perfusion solution or in the dialysis liquid, on the respective flow rates thereof, and on the flow rate of the patient's blood through the membrane exchanger, the main problem at the basis of document EP0678301 is that the concentration of bicarbonate in the blood of the patient corresponds rarely exactly to the desired concentration. EP0678301 describes a blood treatment device including a dialyzer with two chambers separated by a membrane. A dialysis liquid container (that does not contain any bicarbonate) is connected to a fluid pump via a duct which runs to the second chamber of the dialyzer. Electromagnetic clamps are provided for connecting the container to either the dialyzer or to the blood circuit. A bubble trap is provided in the return line of the blood circuit. The bubble trap is linked to an infusion container containing a solution of bicarbonate. In accordance with EP0678301, the flow rate QHCO3 of the circulation pump is controlled as a function of the flow rate QOUT of the dialysate pump regardless of the type of treatment being delivered to the patient either by the equation:
Q
HCO3
=Q
OUT
*[HCO
3]DES/[HCO3]SOL
or by the equation:
Q
HCO3
=Cl*[HCO
3]DES/[HCO3]SOL
wherein:
Notably, this prior art is directed to proper adjustment of patient blood acid-base equilibrium, by using a specific control of post infusion of bicarbonate solution based on clearance/dialysate flow rate which exclusively works in the following dialysis machine configurations: HF with post dilution and HD(F) with post dilution. Therefore, the problem of proper acid-base management in configuration wherein citrate is infused pro-blood pump (e.g., regional anticoagulation systems) and/or bicarbonate containing solution is pre-infused remains unsolved.
As to adapting to specific patient condition, protocols may (by far not systematically) include guidelines for adjusting citrate infusion or dialysis fluid/replacement flow rates in case patient monitoring data evidence alkalosis or acidosis problems. When present, these guidelines appear largely empirical. In the case of acidosis, some literature report for the infusion of bicarbonate ‘bolus’. Although some published protocols are derived from some upstream modelling, no parameter representative of the expected buffer balance from the therapy is made explicitly available, whatever ‘original’ protocol parameters are used or after these have been tuned further to patient monitoring data. As to date, anticipation and control of acid base-balance during CRRT, particularly when using regional citrate anticoagulation (RCA) remains a difficult question especially when intending to use non-proven prescriptions.
In this situation, it is a general object of the present embodiments to offer a technical solution capable overcoming one or more of the above drawbacks.
More in detail, it is an object of the present embodiments to render available a CRRT medical apparatus for the extracorporeal treatment of blood and a process configured for providing assisted prescription, at the same time taking into consideration the proper acid-base blood balance, particularly in the context of regional anticoagulation. In detail, it is an aim of the present embodiments to allow for acid-balance control/management, wherein the system is also designed to vary buffer balance of the extracorporeal blood circuit in an easy, but safe and controlled way.
It is an aim to provide an apparatus and a method allowing to property calculate set flow rates keeping an eye towards a proper buffer balance and capable of reducing as much possible the actions required for setting up the apparatus. Is a further object of aspects of the invention to define an apparatus and a process allowing the operator to set up a CRRT blood treatment apparatus using medically meaningful parameters, which may result in an easier to use user interface. In particular, it is an aim to provide an assisted prescription in a situation where prescription includes a parameter specifying a steady state acid-base balance target, parameter which is of specific importance in the case of citrate anticoagulation
It is an auxiliary object of the invention to offer a medical apparatus for the treatment of fluid and a process for calculating set flow rates in said apparatus which may facilitate flow rate setting before and during the treatment- and optimize the consumption of fluid with respect to the prescription target and the system constraints.
Another auxiliary object is an apparatus capable of controlling operating parameters in a safe manner.
At least one of the above objects is substantially reached by an apparatus according to one or more of the appended apparatus claims. One or more of the above objects is also substantially reached by a process according to any one of the appended process claims.
Apparatus and processes according to aspects of the invention are here below described.
A 1st independent aspect concerns a Continuous Renal Replacement Therapy (CRRT) apparatus comprising: a filtration unit (2) having a primary chamber (3) and a secondary chamber (4) separated by a semi-permeable membrane (5);
In an aspect according to the previous aspect, receiving a patient prescription comprises allowing entry of a set value for a prescribed dialysis dose (Dset) to be delivered, and determining one or more operating parameters comprises determining at least two operating parameters, the determining of the operating parameters comprises calculating a set value of at least two fluid flow rates selected in the group, calculating the set value of at least two fluid flow rates is based at least on said set value of the prescribed dialysis dose (Dset) and on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood.
A further independent aspect is directed to a process of setting up a Continuous Renal Replacement Therapy (CRRT) apparatus, the apparatus comprising:
In another independent aspect, a Continuous Renal Replacement Therapy (CRRT) apparatus is provided comprising: a filtration unit (2) having a primary chamber (3) and a secondary chamber (4) separated by a semi-permeable membrane (5);
Notably and in accordance with the previous aspects, calculating each set value of the at least two fluid flow rates is based at least on both said set value of the prescribed dialysis dose (Dset) and on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood. For example, a first fluid flow rate from the list (e.g., the fluid flow rate (Qrep_post) through the post-dilution infusion line (63)) is calculated based on both the set value of the prescribed dialysis dose (Dset) and on the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood and a second fluid flow rate from the list (e.g., the fluid flow rate (Qdial) through the dialysis liquid supply line (8)) is calculated based on both the set value of the prescribed dialysis dose (Dset) and on the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood.
In a further independent aspect, a Continuous Renal Replacement Therapy (CRRT) apparatus is provided comprising:
In a further aspect in accordance with any one of the previous aspects, said at least another fluid flow rate (or one of the at least two flow rates) is either:
In a 2nd aspect according to any one of the previous aspects the anticoagulant infusion line (51) connected at one end thereof to the blood withdrawal line in a region of the blood withdrawal line which is positioned in use upstream from the blood pump (21) and an anticoagulant source (10) connected at an opposite end of the anticoagulant infusion line (51), wherein receiving a patient prescription further comprises allowing entry of a set value for a regional anticoagulation dose (Dcit), in particular a citrate dose, indicative of an intensity of the regional anticoagulation.
In a 3rd aspect according to the preceding aspect, the regional anticoagulation dose (Dcit) has the same unit as a concentration and is in more detail the injected amount of anticoagulant per liter of treated blood (mmol/L blood).
In a 4th aspect according to the preceding two aspects, the control unit (12) is configured to mathematically relate, using a citrate flow rate mathematical relation, the set value for the fluid flow rate (Qcit) through the anticoagulant infusion line (51) with the set value for the regional anticoagulation dose (Dcit), in particular to calculate the set value for the fluid flow rate (Qcit) as a function of the set value for the regional anticoagulation dose (Dcit).
In a 5th aspect according to any one of the preceding three aspects, the control unit (12) is configured to mathematically relate, using a citrate flow rate mathematical relation, the set value for the fluid flow rate (Qcit) through the anticoagulant infusion line (51) with a blood flow rate (Qb) and/or with an anticoagulant, particularly citrate, concentration in the anticoagulant source (10), in particular to calculate the set value for the fluid flow rate (Qcit) as a function of the blood flow rate (Qb) and/or the anticoagulant, particularly citrate, concentration in the anticoagulant source (10).
In a 6th aspect according to any one of the preceding four aspects, said one or more mathematical relations include a citrate flow rate mathematical relation and the fluid flow rate (Qcit) through the anticoagulant infusion line (51) is calculated based on the citrate flow rate mathematical relation stored in said memory (16):
In a 7th aspect according to any one of the preceding aspects, the control unit (12) is configured to drive an anticoagulant pump (54) to infuse anticoagulant in the blood withdrawal line at the calculated fluid flow rate (Qcit) for the anticoagulant.
In a 8th aspect according to any one of the preceding aspects 2 or 3, the regional anticoagulation dose (Dcit) is the fluid flow rate (Qcit) through the anticoagulant infusion line (51).
In a 9th aspect according to any one of the preceding seven aspects, calculating the set value comprises calculating at least three fluid flow rates and is further based at least on said set value of the regional anticoagulation dose (Dcit), in particular using at least one of said one or more mathematical relations.
In a 10th aspect according to any one of the preceding aspects, the CRRT apparatus comprises the ion balancing infusion line (74) connected at one end thereof either to the blood return line (7) or to a patient catheter and a source of ion balancing solution (11) connected at an opposite end of ion balancing infusion line (74), wherein receiving a patient prescription further comprises allowing entry of a set value for an ion re-establishing solution parameter (CaComp; Dca), in particular a calcium compensating parameter, indicative of the intensity of ion balancing, in particular of calcium ions balancing.
In an 11th aspect according to the preceding aspect, the ion re-establishing solution parameter (CaComp) represents a compensation value or compensation percentage of the calcium removed in the filtration unit (2), for example included between 0.05 and 2 or between 5% and 200%.
In a 12th aspect according to the preceding aspect 10, the ion re-establishing solution parameter (Dca) is a, e.g. calcium, dose in terms of an ion, e.g., calcium, concentration, in particular the calcium dose being total calcium concentration in the effluent.
In a 13th aspect according to any one of the preceding three aspects, the control unit (12) is configured to mathematically relate, using a calcium flow rate mathematical relation, the set value for the fluid flow rate (Qca) through the ion balancing infusion line (74) with the set value for the ion re-establishing solution parameter (CaComp; Dca), in particular to calculate the set value for the fluid flow rate (Qca) as a function of the set value for the ion re-establishing solution parameter (CaComp; Dca).
In a 14th aspect according to any one of the preceding four aspects, the control unit (12) is configured to mathematically relate, using a calcium flow rate mathematical relation, the set value for the fluid flow rate (Qca) through the ion balancing infusion line (74) with an effluent flow rate (Qeff), in particular to calculate the set value for the fluid flow rate (Qca) as a function of the effluent flow rate (Qeff).
In a 15th aspect according to any one of the preceding five aspects, the control unit (12) is configured to mathematically relate, using a calcium flow rate mathematical relation, the set value for the fluid flow rate (Qca) through the ion balancing infusion line (74) with a calcium concentration (Cca) in a source of ion balancing solution (11) and/or with a calcium concentration (Cca
In a 16th aspect according to any one of the preceding six aspects, said one or more mathematical relations include a calcium flow rate mathematical relation and wherein the set value for the fluid flow rate (Qca) through the ion balancing infusion line (74) is calculated based on the calcium flow rate mathematical relation stored in the memory (16):
wherein the significance of the denotations is given in the Glossary.
In a 17th aspect according to the preceding aspect 12, said one or more mathematical relations include a calcium flow rate mathematical relation and wherein the set value for the fluid flow rate (Qca) through the ion balancing infusion line (74) is calculated based on the calcium flow rate mathematical relation stored in the memory (16):
wherein the significance of the denotations is given in the Glossary; if any of the infusion lines is missing, the corresponding flow rate is absent from the mathematical relation, or the corresponding flow rate is set to zero.
In a 18th aspect according to any one of the preceding aspects, the control unit (12) is configured to drive an ion balancing pump (75) to infuse an ion re-establishing solution in the blood return line (7) or into the patient (P) at the calculated fluid flow rate (Qca) for ion re-establishing solution.
In a 19th aspect according to any one of the preceding nine aspects, calculating the set value comprises calculating at least three fluid flow rates and is further based at least on said set value for the ion re-establishing solution parameter (CaComp; Dca), in particular using at least one of said one or more mathematical relations.
In a 20th aspect according to any one of the preceding aspects, receiving a patient prescription further comprises allowing entry of a set value for the blood flow rate (Qb) and calculating the set value comprises calculating at least three fluid flow rates and calculating one or more (two or all) set values out of the at least three fluid flow rates is further based at least on said set value for the blood flow rate (Qb), in particular using at least one of said one or more mathematical relations.
In a 21th aspect according to any one of the preceding aspects, receiving a patient prescription further comprises allowing entry of a set value for at least a fluid removal rate (QPFR) from the patient and calculating the set value comprises calculating at least three fluid flow rates and calculating one or more (two or all) set values out of the at least three fluid flow rates is further based at least on said set value for the fluid removal rate (QPFR) from the patient, in particular using at least one of said one or more mathematical relations.
In a 22nd aspect according to any one of the preceding aspects, the control unit (12) is configured to mathematically relate, using an effluent flow rate mathematical relation, the fluid flow rate (Qeff) through the effluent fluid line (13) with the set value for the fluid removal rate (QPFR), in particular to calculate the fluid flow rate (Qeff) through the effluent fluid line (13) based on the set value for the fluid removal rate (QPFR).
In a 23rd aspect according to any one of the preceding two aspects, the control unit (12) is configured to mathematically relate, in particular to calculate, the fluid flow rate (Qeff) through the effluent fluid line (13) based on an effluent flow rate mathematical relation comprised in said one or more mathematical relations:
Q
eff
=Q
PBP
+Q
cit
+Q
syr
+Q
dial
+Q
rep.pre
+Q
rep.post
+Q
HCO3
+Q
PFR
+Q
ca
wherein the significance of the denotations is given in the Glossary; if any of the infusion lines or the dialysis liquid supply line is missing, the corresponding flow rate is absent from the mathematical relation, or the corresponding flow rate is set to zero.
In a 24th aspect according to any one of the preceding aspects, the CRRT apparatus comprises a fluid source of a solution supplying fluid to one of said one or more further fluid lines, said solution comprising at least one buffer agent in the form of bicarbonate or bicarbonate precursor.
In a 25th aspect according to the preceding aspect, the bicarbonate precursor includes citrate, lactate and/or acetate.
In a 26th aspect according to any one of the preceding aspects, the parameter (nNBL) indicative of a steady state acid-base balance in the blood of the patient undergoing a CRRT treatment is a parameter function of a net buffer load (NBL) in the patient expected at a steady state, wherein the net buffer load is a sum of bicarbonate generation from bicarbonate precursor metabolism, such as citrate or lactate metabolism, bicarbonate balance in the extracorporeal blood circuit (17) and/or of bicarbonate infusions into the patient and/or of acid infusion in the extracorporeal blood circuit (17), such as citric acid infusion.
In a 27th aspect according to the preceding aspect, the net buffer load is a normalized net buffer (nNBL) load in the patient expected at a steady state, particularly normalized over a patient body weight (BW), in more detail the parameter (nNBL) indicative of a steady state acid-base balance in the blood of the patient undergoing a CRRT treatment being the net buffer load (NBL) or the normalized net buffer load (nNBL):
In a 28th aspect according to any one of the preceding aspects, the parameter (nNBL) indicative of a steady state acid-base balance in the blood of the patient is based on one or more of, and in particular the four of:
In a 29th aspect according to the preceding aspect, the parameter (nNBL) indicative of a steady state acid-base balance in the blood of the patient is an algebraic sum of the estimation of bicarbonate form precursor metabolism (Jmet_cit; Jlact), the bicarbonate balance (JHCO3_bat), and the acid infusion (JH+), in particular the acid infusion (JH+) being a negative term providing a loss in patient buffer.
In a 30th aspect according to the preceding aspect, the parameter (nNBL) indicative of a steady state acid-base balance in the blood of the patient is defined as follows:
alternatively, when also lactate balance is considered, the parameter (nNBL) indicative of a steady state acid-base balance in the blood of the patient is defined as follows:
In a 31th aspect according to any one of the preceding aspects, the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient is based on an acid infusion (JH+) from citric acid contained in the fluid source in terms of an amount per unit of time, wherein the acid infusion (JH+) is a function of a citric acid concentration (Ccitric_pbp) and of an infusion rate (Qcit) of citric acid, in particular the acid infusion (JH+) being equal to 3 times the citric acid concentration (Ccitric_pbp) times the infusion rate (Qcit) of citric acid.
In a 32nd aspect according to any one of the preceding aspects, the parameter (nNBL) indicative of a steady state acid-base balance in the blood of the patient undergoing a CRRT treatment is a parameter defined assuming a constant value for patient plasma bicarbonate concentration (CpHCO3_pat0), said constant value being for example 25 mM.
In a 33rd aspect according to any one of the preceding aspects, the parameter (CpHCO3_pat) indicative of a steady state bicarbonate concentration in the blood of the patient is based on an estimated net buffer load (Jbuffer_load/BW) indicative of a steady state acid-base balance in the blood of the patient.
In a further aspect according to any one of the preceding aspects, the parameter (CpHCO3_pat) indicative of a steady state bicarbonate concentration in the blood of the patient is defined imposing a constant value for a normalized net buffer load (NBL) for the patient at steady state, said constant value being for example NBL=nNBL0·BW=0.1 mmol/h/kg.
In a 34th aspect according to any one of the preceding aspects, the parameter (CpHCO3_pat) indicative of a steady state bicarbonate concentration in the blood of the patient is defined imposing a constant value for the normalized net buffer load (NBL) for the patient at steady state, said constant value being for example nNBL0·BW=001 mmol/h/kg.
In a 35th aspect according to any one of the preceding aspects, said one or more mathematical relations include steady state bicarbonate indicator mathematical relations, and wherein the steady state bicarbonate indicator mathematical relations links the parameter (CpHCO3_pat) indicative of a steady state bicarbonate concentration in the blood of the patient with said at least two flow rates in the group.
In a 36th aspect according to any one of the preceding aspects, said one or more mathematical relations include steady state bicarbonate indicator mathematical relations, and wherein the steady state bicarbonate indicator mathematical relations links the parameter (CpHCO3_pat) indicative of a steady state bicarbonate concentration in the blood of the patient with one or more of the fluid flow rate (Qrep.pre) through the pre-dilution infusion line (29), the fluid flow rate (Qdial) through the dialysis liquid supply line (8), the fluid flow rate (Qcit) through the anticoagulant infusion line (51), the fluid flow rate (QPBP) through the PBP infusion line (52), in particular links the parameter (CpHCO3_pat) with the fluid flow rate (Qrep.pre; Qdial; Qcit; QPBP) times the respective bicarbonate concentration (CHCO3rep.pre; CHCO3
In a 37th aspect according to any one of the preceding aspects, said one or more mathematical relations include steady state bicarbonate indicator mathematical relations, and wherein the steady state bicarbonate indicator mathematical relations links the parameter (CpHCO3_pat) indicative of a steady state bicarbonate concentration in the blood of the patient with the blood flow rate (Qb), in particular a blood water flow rate (Qbw) and/or a blood water flow rate (Qbw_inlet) at the inlet of the filtration unit (2).
In a 38th aspect according to any one of the preceding aspects, said one or more mathematical relations include steady state bicarbonate indicator mathematical relations, and wherein the steady state bicarbonate indicator mathematical relations links the parameter (CpHCO3_pat) indicative of a steady state bicarbonate concentration in the blood of the patient with a bicarbonate concentration (CHCO3
In a 39th aspect according to any one of the preceding aspects, said one or more mathematical relations include steady state bicarbonate indicator mathematical relations, and wherein the steady state bicarbonate indicator mathematical relations links the parameter (CpHCO3_pat) indicative of a steady state bicarbonate concentration in the blood of the patient with a bicarbonate plasma water concentration CpwHCO3_inlet at filtration unit inlet.
In a 40th aspect according to any one of the preceding aspects, said one or more mathematical relations include steady state bicarbonate indicator mathematical relations, and wherein the steady state bicarbonate indicator mathematical relations links the parameter (CpHCO3_pat) indicative of a steady state bicarbonate concentration in the blood of the patient with an ultrafiltration flow rate (Qfil) in the filtration unit (2), in particular with the ultrafiltration flow rate (Qfil) times a bicarbonate concentration (CHCO3
In a 41th aspect according to any one of the preceding aspects, said one or more mathematical relations include steady state bicarbonate indicator mathematical relations, and wherein the steady state bicarbonate indicator mathematical relations links the parameter (CpHCO3_pat) indicative of a steady state bicarbonate concentration in the blood of the patient with a bicarbonate removal (JHCO3_eff) into spent dialysate flowing in the effluent line (13).
In a 42nd aspect according to any one of the preceding aspects, said one or more mathematical relations include steady state bicarbonate indicator mathematical relations, and wherein the steady state bicarbonate indicator mathematical relations are the following:
wherein the significance of the denotations is given in the Glossary; if any of the infusion lines or the dialysis liquid supply line is missing, the corresponding flow rate is absent from the mathematical relation, or the corresponding flow rate is set to zero.
Note that if CpHCO3_pat is taken as the parameter indicative of a steady state acid-base balance in the blood of the patient, then nNBL will have to be (implicitly) taken as a constant, namely nNBL0; if vice versa, nNBL is taken as the parameter indicative of a steady state acid-base balance in the blood of the patient, then CpHCO3_pat will have to be (implicitly) taken as a constant, namely CpHCO3_pat0.
In a 43rd aspect according to any one of the preceding aspects, the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient affects the set value of the fluid flow rate (Qrep.pre) through the pre-dilution infusion line (29), the set value of the fluid flow rate (Crep.pre) through the pre-dilution infusion line (29) being an operating parameter calculated by the control unit (12). In particular, this is one of the at least two flow rates calculated based on the set value of the prescribed dialysis dose (Dset) and on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood.
In a 44th aspect, according to any one of the preceding aspects, the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient affects the set value of the fluid flow rate (Qrep.post) through the post-dilution infusion line (63), affects the set value of the fluid flow rate (Qrep.post) through the post-dilution infusion line (63) being an operating parameter calculated by the control unit (12). In particular, this is one of the at least two flow rates calculated based on the set value of the prescribed dialysis dose (Dset) and on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood.
In a 45th aspect according to any one of the preceding aspects, the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient affects the set value of the fluid flow rate (QHCO3) through the post-dilution bicarbonate infusion line (23), the set value of the fluid flow rate (QHCO3) through the post-dilution bicarbonate infusion line (23) being an operating parameter calculated by the control unit (12). In particular, this is one of the at least two flow rates calculated based on the set value of the prescribed dialysis dose (Dset) and on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood.
In a 46th aspect according to any one of the preceding aspects, the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient affects the set value of the fluid flow rate (Qca) through the ion balancing infusion line (74), the set value of the fluid flow rate (Qca) through the ion balancing infusion line (74) being an operating parameter calculated by the control unit (12). In particular, this is one of the at least two flow rates calculated based on the set value of the prescribed dialysis dose (Dset) and on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood.
In a 47th aspect according to any one of the preceding aspects, the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient affects the set value of the fluid flow rate (Qdial) through the dialysis liquid supply line (8), the set value of the fluid flow rate (Qdial) through the dialysis liquid supply line (8) being an operating parameter calculated by the control unit (12). In particular, this is one of the at least two flow rates calculated based on the set value of the prescribed dialysis dose (Dset) and on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood.
In a 48th aspect according to any one of the preceding aspects, the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient affects the set value of the fluid flow rate (Qcit) through the anticoagulant infusion line (51), particularly in case the set value for the blood fluid flow rate (Qb) through the extracorporeal blood circuit (17) is determined by the control unit (12) as an operating parameter, the set value of the fluid flow rate (Qcit) through the anticoagulant infusion line (51) being an operating parameter calculated by the control unit (12). In particular, this is one of the at least two flow rates calculated based on the set value of the prescribed dialysis dose (Dset) and on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood.
In a 49th aspect according to any one of the preceding aspects, the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient affects the set value of the fluid flow rate (QPBP) through the PBP infusion line (52), the set value of the fluid flow rate (QPBP) through the PBP infusion line (52) being an operating parameter calculated by the control unit (12). In particular, this is one of the at least two flow rates calculated based on the set value of the prescribed dialysis dose (Dset) and on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood.
In a 50th aspect according to any one of the preceding aspects, the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient affects the set value of the blood fluid flow rate (Qb) through the extracorporeal blood circuit (17), the set value of the blood fluid flow rate (Qb) through the extracorporeal blood circuit (17) being an operating parameter calculated by the control unit (12). In particular, this is one of the at least two flow rates calculated based on the set value of the prescribed dialysis dose (Dset) and on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood.
In a51st aspect according to any one of the preceding aspects, the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient affects the set value of the fluid flow rate (Qeff) through the effluent fluid line (13), the set value of the fluid flow rate (Qeff) through the effluent fluid line (13) being an operating parameter calculated by the control unit (12). In particular, this is one of the at least two flow rates calculated based on the set value of the prescribed dialysis dose (Dset) and on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood.
Notably, the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient is used for the calculation of the majority and specifically all the above indicated fluid flow rates, when relevant (i.e., if the lines is present and the applied treatment requires use of the line with a set flow rate different from zero).
In a 52nd aspect according to any one of the preceding aspects, at least a number of said one or more mathematical relations correlates the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient who has to undergo a CRRT blood treatment with the at least two fluid flow rates selected in said group.
In a 53rd aspect according to any one of the preceding aspects, calculating the set value of the fluid flow rate (Qcit) through the anticoagulant infusion line (51) is based at least on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood and/or on said set value of the prescribed dialysis dose (Dset), particularly in case the set value for the blood fluid flow rate (Qb) through the extracorporeal blood circuit (17) is determined by the control unit (12) as an operating parameter,
In a 54th aspect according to any one of the preceding aspects, calculating the set value of the fluid flow rate (QPBP) through the PBP infusion line (52) is based at least on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood and/or on said set value of the prescribed dialysis dose (Dset), in particular wherein the control unit (12) calculates the set value of the fluid flow rate (QPBP) through the PBP infusion line (52) using said mathematical relations.
In a 55th aspect according to any one of the preceding aspects, calculating the set value of the fluid flow rate (Qrep.pre) through the pre-dilution infusion line (29) is based at least on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood and/or on said set value of the prescribed dialysis dose (Dset), in particular wherein the control unit (12) calculates the set value of the fluid flow rate (Qrep/pre) through the pre-dilution infusion line (29) using said mathematical relations.
In a 56th aspect according to any one of the preceding aspects, calculating the set value of the fluid flow rate (Qrep.post) through the post-dilution infusion line (63) is based at least on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood and/or on said set value of the prescribed dialysis dose (Dset), in particular wherein the control unit (12) calculates the set value of the fluid flow rate (Qrep.post) through the post-dilution infusion line (63) using said mathematical relations.
In a 57th aspect according to any one of the preceding aspects, calculating the set value of the fluid flow rate (QHCO3) through the post-dilution bicarbonate infusion line (23) is based at least on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood and/or on said set value of the prescribed dialysis dose (Dset), in particular wherein the control unit (12) calculates the set value of the fluid flow rate (QHCO3) through the post-dilution bicarbonate infusion line (23) using said mathematical relations.
In a 58th aspect according to any one of the preceding aspects, calculating the set value of the fluid flow rate (Qca) through the ion balancing infusion line (74) is based at least on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood and/or on said set value of the prescribed dialysis dose (Dset), in particular wherein the control unit (12) calculates the set value of the fluid flow rate (Qca) through the ion balancing infusion line (74) using said mathematical relations.
In a 59th aspect according to any one of the preceding aspects, calculating the set value of the blood fluid flow rate (Qb) through the extracorporeal blood circuit (17) is based at least on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood and/or on said set value of the prescribed dialysis dose (Dset), in particular wherein the control unit (12) calculates the set value of the fluid flow rate (Qb) through the extracorporeal blood circuit (17) using said mathematical relations.
In a 60th aspect according to any one of the preceding aspects, calculating the set value of the fluid flow rate (Qdial) through the dialysis liquid supply line (8) is based at least on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood and/or on said set value of the prescribed dialysis dose (Dset), in particular wherein the control unit (12) calculates the set value of the fluid flow rate (Qdial) through the dialysis liquid supply line (8) using said mathematical relations.
In a 61sh aspect according to any one of the preceding aspects, calculating the set value of the fluid flow rate (Qeff) through the effluent fluid line (13) is based at least on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood and/or on said set value of the prescribed dialysis dose (Dset), in particular wherein the control unit (12) calculates the set value of the fluid flow rate (Qeff) through the effluent fluid line (13) using said mathematical relations.
In a 62nd aspect according to any one of the preceding aspects, wherein said one or more mathematical relations include a net buffer load mathematical relation linking the the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood with at least one, and particularly all, of
J
buffer_load
=J
met_cit
+J
HCO3
+J
met_lact
−J
H+
wherein the significance of the denotations is given in the Glossary; if any of the mass transfer rate is missing, the corresponding mass transfer term is absent from the mathematical relation, or the corresponding value is set to zero.
In a 63rd aspect according to any one of the preceding aspects, said one or more mathematical relations include a bicarbonate balance mathematical relation based on a bicarbonate balance (JHCO3_BAL) from the CRRT blood treatment to be delivered in terms of an amount per unit of time, in particular wherein the bicarbonate balance (JHCO3_bal) is the difference between a bicarbonate infusion rate from the dialysis liquid supply line (8) and/or the infusion lines (JHCO3_inf) and the bicarbonate removal into dialysate (JHCO3_dial), in particular the bicarbonate balance mathematical relation is:
J
HCO3_bal
=J
HCO3_Inf
−J
HCO3_eff
wherein the significance of the denotations is given in the Glossary; if any of the mass transfer rate is missing, the corresponding mass transfer term is absent from the mathematical relation, or the corresponding value is set to zero.
In a 64th aspect according to the preceding aspect, bicarbonate infusion rate (JHCO3_inf) from the dialysis liquid supply line (8) is a function of the fluid flow rate (Qdial) through the dialysis liquid supply line (8) and bicarbonate concentration (CHCO3
In a 65th aspect according to any one of the preceding two aspects, bicarbonate infusion rate (JHCO3_inf) from the infusion lines is a function of the fluid flow rate/s (Qrep.pre; Qrep.post; Qcit; QPBP; QHCO3; Qca) and the respective bicarbonate concentration (CHCO3
In a 66th aspect according to any one of the preceding three aspects, said one or more mathematical relations include a bicarbonate infusion mathematical relation and wherein the bicarbonate infusion rate from the dialysis liquid supply line (8) and the infusion lines (JHCO3_inf) is particularly according to the bicarbonate infusion mathematical relation:
J
HCO3_Inf
=Q
dial
·C
HCO3
+Q
rep.pre
·C
HCO3
+Q
rep.post
·C
HCO3
+Q
HCO3
·CHCO3
wherein the significance of the denotations is given in the Glossary; if any of the infusion lines or the dialysis liquid supply line is missing, the corresponding flow rate is absent from the mathematical relation, or the corresponding flow rate is set to zero.
In a 67th aspect according to any one of the preceding four aspects, the bicarbonate removal into spent dialysate (JHCO3_eff) in the effluent line (13) is a function of the fluid flow rate (Qdial) through the dialysis liquid supply line (8) and bicarbonate concentration (CHCO3
In a 68th aspect according to any one of the preceding five aspects, the bicarbonate removal into spent dialysate UHCO3_eff) in the effluent line (13) is a function of bicarbonate concentration in the dialysis fluid (CHCO3_dial), in particular as a function of a difference between bicarbonate plasma water concentration at filter inlet (CpwHCO3_inlet) and bicarbonate concentration in the dialysis fluid (CHCO3_dial).
In a 69th aspect according to any one of the preceding six aspects, the bicarbonate removal into spent dialysate (JHCO3_eff) in the effluent line (13) is a function of an ultrafiltration flow rate (Qfil) in the filtration unit (2) and bicarbonate concentration (CHCO3
In a 70th aspect according to any one of the preceding seven aspects, the bicarbonate removal into spent dialysate (JHCO3_eff) in the effluent line (13) is a function of a bicarbonate clearance (KHCO3).
In a 71st aspect according to any one of the preceding eight aspects, the bicarbonate removal into spent dialysate (JHCO3_eff) in the effluent line (13) is a function of the fluid flow rate (Qeff) through the effluent fluid line (13), in particular wherein a bicarbonate clearance (KHCO3) is estimated equal to said effluent fluid flow rate (Qeff).
In a 72nd aspect according to any one of the preceding aspects, the bicarbonate removal into spent dialysate (JHCO3_eff) in the effluent line (13) is a function of a bicarbonate clearance (KHCO3) and the bicarbonate clearance (KHCO3) is a function of one or more flow rates, particularly including one or more of the fluid flow rate (Qdial) through the dialysis liquid supply line (8), an ultrafiltration rate (Qfil) in filtration unit (2), and a blood water flow rate (Qbw
In a 73rd aspect according to the preceding aspect, the bicarbonate clearance (KHCO3) is a function of the filtration unit (2) intended for CRRT treatment, in particular as a function of a sieving coefficient (SCHCO3) for bicarbonate and/or a ratio of filtration unit surface area to diffusive mass transfer resistance (S/RTHCO3) for bicarbonate.
In a 74th aspect according to any one of the preceding aspects, said one or more mathematical relations include bicarbonate clearance mathematical relations as follows:
wherein the significance of the denotations is given in the Glossary; if any of the infusion lines or the dialysis liquid supply line is missing, the corresponding flow rate is absent from the mathematical relation, or the corresponding flow rate is set to zero.
It is noted that above equations do not work with Qdial=0 or Qfil=0; in such situations it is possible to remove the infinite value by (artificially) replacing 0 value for either or both Qdial and/or Qfil by e.g., 1 or 0.1 ml/h. Otherwise specific equations for pure CWHD or pure CWH may be alternatively used.
In a 75th aspect according to any one of the preceding aspects, said one or more mathematical relations include an ultrafiltration flow rate mathematical relation linking an ultrafiltration flow rate (Qfil) through the filtration unit (2) with a fluid removal rate (QPFR) from the patient and infusion flow rate/s (QPBP, Qcit, Qrep.pre, Qrep.post, QHCO3, Qca) in the extracorporeal blood circuit (17), in particular according to:
Q
fil
=Q
PBP
+Q
cit
+Q
syr
+Q
rep.pre
+Q
rep.post
+Q
HCO3
+Q
PFR
+Q
ca
wherein the significance of the denotations is given in the Glossary; if any of the infusion lines is missing, the corresponding flow rate is absent from the mathematical relation, or the corresponding flow rate is set to zero.
In a 76th aspect according to any one of the preceding aspects, said one or more mathematical relations include a blood water flow rate mathematical relation linking a blood water flow rate (Qbw) to the blood fluid flow rate (Qb) and haematocrit (Hct), in particular according to:
Qbw=Q
b·[(1−Hct)·Fp+Hct·Frbc]
wherein the significance of the denotations is given in the Glossary.
In a 77th aspect according to any one of the preceding aspects, said one or more mathematical relations include a blood water flow rate at filtration unit inlet mathematical relation linking blood water flow rate Qbwinlet at the filtration unit inlet to one or more of a blood water flow rate (Qbw), the fluid flow rate (Qcit) through the anticoagulant infusion line (51), the fluid flow rate (QPBP) through the PBP infusion line (52), and the fluid flow rate (Qrep.pre) through the pre-dilution infusion line (29), in particular blood water flow rate at filtration unit inlet mathematical relation being as follows:
Qbw
inlet
=Q
bw
+Q
cit
+Q
PBP
+Q
rep.pre
+Q
syr=
Q
b·[(1−Hct)·Fp+Hct·Frbc]+Qcit+QPBP+Qrep.pre+Qsyr
wherein the significance of the denotations is given in the Glossary.
In a 78th aspect according to any one of the preceding aspects, said one or more mathematical relations include a bicarbonate removal mathematical relation, in particular wherein the bicarbonate removal mathematical relation is:
J
HCO3_eff
=Q
dial
·C
HCO3
+K
HCO3·(CpwHCO3_inlet−CHCO3_dial)+Qfil·CHCO3_dial
wherein the significance of the denotations is given in the Glossary.
In a 791 aspect according to any one of the preceding aspects, said one or more mathematical relations include a plasma water concentration at filter inlet mathematical relation correlating the bicarbonate plasma water concentration at filter inlet (CpwHCO3_inlet) as a function of flow rates including one or more of blood water flow rate (Qbw), blood water flow rate at filter inlet (Qbwinlet), the fluid flow rate (Qcit) through the anticoagulant infusion line (51), the fluid flow rate (QPBP) through the PBP infusion line (52) and the fluid flow rate (Qrep.pre) through the pre-dilution infusion line (29) and/or as a function of bicarbonate concentrations (CHCO3
In an 80th aspect according to the preceding aspect, said plasma water concentration at filter inlet mathematical relation is:
wherein the significance of the denotations is given in the Glossary; if any of the infusion lines is missing, the corresponding flow rate is absent from the mathematical relation, or the corresponding flow rate is set to zero.
In an 81a aspect according to any one of the preceding aspects, said one or more mathematical relations include a bicarbonate balance mathematical relation based on a bicarbonate balance (JHCO3_bal) from the CRRT blood treatment to be delivered in terms of an amount per unit of time, in particular the bicarbonate balance mathematical relation is:
wherein the significance of the denotations is given in the Glossary; if any of the infusion lines or the dialysis liquid supply line is missing, the corresponding flow rate is absent from the mathematical relation, or the corresponding flow rate is set to zero.
Note that the above equation assumes that no bicarbonate is present in the ion replacement (Ca) solution.
In an 82nd aspect according to any one of the preceding aspects, the net buffer load mathematical relation of aspect 62 and the bicarbonate balance mathematical relation of aspect 81 (or alternatively aspects 63+66+78) link the the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood with the at least two fluid flow rates selected in the group, the control unit (12) using the net buffer load mathematical relation of aspect 62 and the bicarbonate balance mathematical relation of aspect 81 (or alternatively aspects 63+66+78) to calculate the set value of said at least two fluid flow rates.
In an 83rd aspect according to the preceding aspect, the mathematical relations of aspects 75, 76, 77 and 78 are further used by the control unit (12) to calculate the set value of said at least two flow rates.
In an 84th aspect according to any one of the preceding aspects, said one or more mathematical relations include a citrate load mathematical relation based on a citrate load (Jcit_load) to the patient in terms of an amount per unit of time, in particular wherein the citrate load (Jcit_load) is the difference between a citrate infusion rate (Jcit_PBP) through the anticoagulant infusion line (51) and a citrate removal rate to effluent (Jcit_dial) in the effluent line (13), in particular the citrate load mathematical relation is:
J
citrate_load
=J
cit_PBP
−J
cit_dial
wherein the significance of the denotations is given in the Glossary; if any of the mass transfer rate is missing, the corresponding mass transfer term is absent from the mathematical relation, or the corresponding value is set to zero. In an 85, aspect according to the preceding aspect, the citrate load (Jcit_load), in particular the citrate removal rate to effluent (Jcit_dial), is a function of patient citrate metabolic clearance (Kcit_met), in particular the metabolic clearance being based on, e.g., directly proportional to, a patient body weight (BW), for example being determined as follows:
wherein patient citrate metabolic clearance (Kcit_met) is measured as [ml/min] and body weight (BW) is measured as [kg].
In an 86th aspect according to any one of the preceding two aspects, the citrate load (Jcit_load) is a function of citrate clearance (Kcit).
An 87th aspect according to any one of the preceding three aspects, the citrate load (Jcit_load) is a function of the fluid flow rate (Qeff) through the effluent fluid line (13), in particular wherein a citrate clearance (Kcit) is estimated equal to said effluent fluid flow rate (Qeff).
In an 88th aspect according to any one of the preceding aspects, the citrate load (Jcit_load) is a function of a citrate clearance (Kcit) and, according to citrate clearance mathematical relations of said one or more mathematical relations, the citrate clearance (Kcit) is a function of one or more flow rates, particularly including one or more of the fluid flow rate (Qdial) through the dialysis liquid supply line (8), an ultrafiltration rate (Qfil) in filtration unit (2), and a plasma water flow rate (Qpwinlet) at the filtration unit inlet.
In an 89th aspect according to the preceding aspect, the citrate load (Jcit_load) is a function of the filtration unit (2) intended for CRRT treatment, in particular as a function of a sieving coefficient (SCcit) for citrate and/or a ratio of filtration unit surface area to diffusive mass transfer resistance (S/RTcit) for citrate.
In a 90th aspect according to the one of the preceding aspects, said one or more mathematical relations include citrate clearance mathematical relations as follows:
wherein the significance of the denotations is given in the Glossary; if any of the infusion lines or the dialysis liquid supply line is missing, the corresponding flow rate is absent from the mathematical relation, or the corresponding flow rate is set to zero.
In a 91st aspect according to any one of the preceding aspects, said one or more mathematical relations include a plasma flow rate mathematical relation linking a plasma flow rate (Qp) to the blood fluid flow rate (Qb) and haematocrit (Hct), in particular according to:
Qp=Q
b·(1−Hct)
wherein the significance of the denotations is given in the Glossary.
In a 92nd aspect according to any one of the preceding aspects, said one or more mathematical relations include a plasma water flow rate mathematical relation linking a plasma water flow rate (Qpw) to the blood fluid flow rate (Qb) and haematocrit (Hct), in particular according to:
Qpw=Q
b·(1−Hct)·Fp
wherein the significance of the denotations is given in the Glossary.
In a 93rd aspect according to any one of the preceding aspects, said one or more mathematical relations include a plasma water flow rate at filtration unit inlet mathematical relation linking plasma water flow rate Qpwinlet at the filtration unit inlet to one or more of a plasma water flow rate (Qpw), the fluid flow rate (Qcit) through the anticoagulant infusion line (51), the fluid flow rate (QPBP) through the PBP infusion line (52), and the fluid flow rate (Qrep.pre) through the pre-dilution infusion line (29), in particular blood water flow rate at filtration unit inlet mathematical relation being as follows:
Qpw
inlet
=Qpw+Q
cit
+Q
syr
+Q
PBP
+Q
rep.pre=
Q
b·(1−Hct)·Fp+Qcit+QPBP+Qrep.pre
wherein the significance of the denotations is given in the Glossary; if any of the infusion lines or the dialysis liquid supply line is missing, the corresponding flow rate is absent from the mathematical relation, or the corresponding flow rate is set to zero.
In a 94th aspect according to any one of the preceding aspects, a citrate load (Jcit_load) is alternatively a function of a citrate dose (Dcit) and the blood flow (Qb), namely according to Dcit·Qb, or a function of the citrate flow rate (Qcit) in the anticoagulant line (51) and a total citrate concentration (Ccit_-pbp), namely according to Qcit·Ccit
In a 95th aspect according to any one of the preceding aspects, said one or more mathematical relations include a citrate load mathematical relation linking a citrate load (Jcit_load) with a citrate dose (Dcit) and/or the blood flow rate (Qb) and/or a citrate clearance (Kcit) and/or plasma water flow rate (Qpw_inlet) at the inlet of the filtration unit (2), in particular wherein the citrate load mathematical relation is either:
wherein the significance of the denotations is given in the Glossary.
In a 96th aspect according to any one of the preceding aspects, the net buffer load mathematical relation of aspect 67 and the citrate load mathematical relation of aspect 95 link the the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood with the at least two fluid flow rates selected in the group, the control unit (12) uses the net buffer load mathematical relation of aspect 67 and the citrate load mathematical relation of aspect 95 to calculate the set value of said at least two fluid flow rates.
In a 97th aspect according to the preceding aspect, the mathematical relations of aspects 85, 90, 91, 92 and 83 are further used by the control unit (12) to calculate the set value of said at least two fluid flow rates.
In a 98th aspect according to any one of the preceding aspects, the control unit (12) is configured to calculate two or more fluid flow rates selected in the group.
In a 99th aspect according to any one of the preceding aspects, the control unit (12) is configured to calculate three or more fluid flow rates selected in the group.
In a 100th aspect according to any one of the preceding aspects, the control unit (12) is configured to calculate four or more fluid flow rates selected in the group.
In a 101st aspect according to any one of the preceding aspects, the control unit (12) is configured to receive a number ‘n’ of clinical prescription parameters and to calculate a plurality ‘m’ of fluid flow rates selected in the group, wherein the plurality of fluid flow rates is higher or equal to the number clinical prescription parameters, namely m≥n.
In a 102nd aspect according to any one of the preceding aspects, the control unit (12) is configured to receive a number ‘n’ of clinical prescription parameters comprising said prescribed dialysis dose (Dset) and said parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient and one or more of
In a 103rd aspect according to any one of the preceding two aspects, if m>n, the control unit (12) provides for additional therapy configuration parameters to be selectable, said additional therapy configuration parameters adding further mathematical relations to be used for calculating the ‘m’ fluid flow rates, in particular, if m=n+1, one additional therapy configuration parameter is selectable, if m=n+2, two additional therapy configuration parameters are selectable.
In a 104th aspect according to any one of the preceding aspects, said further mathematical relations include one or more of a convection-diffusion relation, a blood pre-dilution relation, and a pre-post infusion relation.
In a 105th aspect according to any one of the preceding aspects, the apparatus is configured for performing regional anticoagulation treatments and comprises:
In a 106th aspect according to the preceding aspect, calculating the set value for at least the fluid flow rate (Qcit) through the anticoagulant infusion line (51) and/or the fluid flow rate (Qca) through the ion balancing infusion line (74), is based at least on said set value of the prescribed dialysis dose (Dset), particularly in case the set value for the blood fluid flow rate (Qb) through the extracorporeal blood circuit (17) is determined by the control unit (12) as an operating parameter.
In a 107th aspect according to the preceding aspect, calculating the set value for at least the fluid flow rate (Qcit) through the anticoagulant infusion line (51) and/or the fluid flow rate (Qca) through the ion balancing infusion line (74), is based at least on said target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood, particularly when the set value for the blood fluid flow rate (Qb) through the extracorporeal blood circuit (17) is determined by the control unit (12) as an operating parameter.
In a 108th aspect according to any one of the preceding aspects, one or more of said mathematical relations correlate the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient to on an estimation of an amount per unit of time of bicarbonate generated from metabolism of citrate (Jmet_cit) infused to the patient, in particular wherein the metabolism of citrate load leads to 3 moles of bicarbonate per mole of citrate at steady state, namely:
J
met_cit=3·Jcit_load.
In a 109th aspect according to any one of the preceding aspects, the control unit (12) is further configured to control said actuators for regulating the flow of fluid based on said set value and calculated value/s of the fluid flow rates.
In a 110th aspect according to any one of the preceding aspects, the actuators for regulating the flow of fluid (24, 25, 26, 31, 53, 54, 65, 75) comprises pumps, e.g., rotational and/or peristaltic pumps, and/or valves.
In a 111th aspect according to any one of the preceding aspects, said one or more mathematical relations correlates the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient who has to undergo a CRRT blood treatment with the at least two fluid flow rates selected in said group.
In a 1121 aspect according to any one of the preceding aspects, the control unit (12) is further configured to calculate the set values of the at least two fluid flow rates by applying said prescribed dose value (Dset) and the target value for the parameter indicative of a steady state acid-base balance in the blood to said mathematical relations.
In a 113th aspect according to any one of the preceding two aspects, the control unit (12) is further configured to calculate the set values of the at least two fluid flow rates by applying the clinical prescription parameters to said mathematical relations.
In a 114th aspect according to any one of the preceding three aspects, the clinical prescription parameters further comprises a fluid removal rate (Qpfr) from the patient to said mathematical relations.
In a 115th aspect according to any one of the preceding four aspects, the clinical prescription parameters further comprises a blood flow rate (Qb) in the extracorporeal blood circuit (17).
In a 116th aspect according to any one of the preceding five aspects, the clinical prescription parameters further comprises the prescribed dialysis dose (Dset) and the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient.
In a 117th aspect according to any one of the preceding six aspects, the clinical prescription parameters further comprises the regional anticoagulation dose (Dcit) and/or the the ion re-establishing solution parameter (CaComp; Dca).
In a 118th aspect according to any one of the preceding aspects, the memory (16) stores a plurality of further mathematical relations correlating the at least two fluid flow rates selected in said group with each other.
In a 119th aspect according to the preceding aspect, the CRRT apparatus comprises—a preset number of pre-dilution lines selected in the group including said pre-dilution infusion line (29) connected at one end thereof to the blood withdrawal line (6), said pre-blood pump—PBP—infusion line (52) connected at one end thereof to the blood withdrawal line in a region of the blood withdrawal line which is positioned in use upstream from the blood pump (21), and said anticoagulant infusion line (51) connected at one end thereof to the blood withdrawal line in a region of the blood withdrawal line which is positioned in use upstream from the blood pump (21);
In a 120th aspect according to the preceding aspect, the convection-diffusion relation defines a first split between the total fluid flow rate (Qrep.pre+Qrep.post+Qpbp+QHCO3+Qca+Qcit) through said preset number of pre- and post-dilution lines and the fluid flow rate (Qdial) through said dialysis liquid supply line (8), in particular the convection-diffusion relation defines a first percentage split or a first ratio R1 dividing the total fluid flow rate (Qrep.pre+Qrep.post+Qpbp+QHCO3+Qca+Qcit) through said preset number of pre- and post-dilution lines by the fluid flow rate (Qdial) through said dialysis liquid supply line (8).
In a 121st aspect according to any one of the preceding two aspects, the blood pre-dilution relation defines a second ratio R2 dividing the total fluid flow rate (Qrep.pre+Qpbp+Qcit) infused in the blood withdrawal line (6) through said preset number of pre-dilution lines by the flow rate of blood (Qb) or of plasma (Qp).
In a 122nd aspect according to any one of the preceding three aspects, the pre-post relation defines a third split between the total fluid flow rate (Qrep.pre+Qpbp+Qcit) through said preset number of pre-dilution lines and total fluid flow rate (Qrep.post+QHCO3+Qca) through said preset number of post-dilution lines, in particular the pre-post relation defines a third percentage split or a third ratio R3 dividing the total fluid flow rate (Qrep.pre+Qpbp+Qcit) through said preset number of pre-dilution lines by total fluid flow rate (Qrep.post+QHCO3+Qca) through said preset number of post-dilution lines.
In a 123rd aspect according to any one of the preceding three aspects, the control (12) unit is further configured to: store a preset value or preset range for each one of said first, second and third splits/ratios R1, R2, R3.
In a 124th aspect according to any one of the preceding four aspects, the control unit (12) is further configured to allow entry by an operator of a set value or a set range for each one of said first, seond and third splits/ratios R1, R2, R3.
In a 125th aspect according to any one of the preceding seven aspects, the control unit (12) is further configured to allow the user to select one or more therapy configurations, said therapy configurations comprising at least one of said further mathematical relations, and optionally two or three of said further mathematical relations, and to calculate the set values of at least two of said fluid flow rates by applying the set value of the prescribed dose (Dset) and the target value of the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient entered by the operator to both the mathematical relations and the further mathematical relation/s selected by the user.
In a 126th aspect according to any one of the preceding aspects, the control unit (12) is further configured to allow the user to select one or more therapy configurations, wherein selecting said therapy configurations comprises choosing the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance in the blood of the patient who has to undergo a CRRT blood treatment between a net buffer load (nNBL; NBL) and a steady state patient bicarbonate (CpHCO3_pat).
In a 127th aspect according to any one of the preceding aspects, the control unit (12) is further configured to allow the user to select one or more therapy configurations, wherein selecting said therapy configurations comprises choosing a definition for the prescribed dialysis dose (Dset).
In a 128th aspect according to any one of the preceding aspects, the control unit (12) is further configured to allow the user to select one or more therapy configurations, wherein selecting said therapy configurations comprises choosing blood flow rate as clinical prescription parameter or as operating parameter.
In a 129th aspect according to any one of the preceding aspects, the control unit (12) is further configured to allow the user to enter treatment configuration values including receiving entries for one or more of
In a 130th aspect according to the preceding aspect, the control unit (12) is further configured to calculate the set values of the at least two fluid flow rates by applying the treatment configuration values to said mathematical relations.
In a 131st aspect according to any one of the preceding two aspects, said substance concentration for one or more containers is entered by an operator for each respective container through a user interface (15) connected to the control unit (12), and/or said substance concentration in the fluid is determined by the control unit (12) associating an identification code on each respective container to a respective substance concentration.
In a 132nd aspect according to any one of the preceding three aspects, said filtration unit parameters for the filtration unit are entered by an operator, and/or said filtration unit parameters are determined by the control unit (12) associating an identification code on the filtration unit (2) to said filtration unit parameters.
In a 133rd aspect according to any one of the preceding aspects, the apparatus comprises the dialysis liquid supply line (8) connected to the inlet of the secondary chamber, wherein the control unit is configured to calculate the set value for the fluid flow rate (Qdial) in the dialysis liquid supply line (8), which is not set by the operator, based on at least a part of the clinical prescription parameters, in particular the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance set by the operator and/or on said prescribed dialysis dose value (Dset).
In a 134th aspect according to any one of the preceding aspects, the apparatus comprises the pr-dilution infusion line (29) connected at one end thereof to the blood withdrawal line (6), in particular the blood pump (21) being active in correspondence of a segment of the blood withdrawal line (6) and the pro-dilution infusion line (29) being connected to the blood withdrawal line (6) downstream the blood pump (21), wherein the control unit is configured to calculate the set value for the fluid flow rate (Qrep.pre) in the pre-dilution infusion line (29), which is not set by the operator, based on at least a part of the clinical prescription parameters, in particular the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance set by the operator and/or on said prescribed dialysis dose value (Dset).
In a 135th aspect according to any one of the preceding aspects, the apparatus comprises the post-dilution infusion line (63) connected at one end thereof to the blood return line (7), wherein the control unit is configured to calculate the set value for the fluid flow rate (Qrep.post) in the post-dilution infusion line (63), which is not set by the operator, based on at least a part of the clinical prescription parameters, in particular the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance set by the operator and/or on said prescribed dialysis dose value (Dset).
In a 136th aspect according to any one of the preceding aspects, the apparatus comprises the post-dilution bicarbonate infusion line (23) connected at one end thereof to the blood return line (7), wherein the control unit is configured to calculate the set value for the fluid flow rate (QHCO3) in the post-dilution bicarbonate infusion line (23), which is not set by the operator, based on at least a part of the clinical prescription parameters, in particular the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance set by the operator and/or on said prescribed dialysis dose value (Dset).
In a 137th aspect according to any one of the preceding aspects, the apparatus comprises the ion balancing infusion line (74) connected at one end thereof either to the blood return line (7) or to a patient catheter, wherein the control unit is configured to calculate the set value for the fluid flow rate (Qca) in the ion balancing infusion line (74), which is not set by the operator, based on at least a part of the clinical prescription parameters, in particular the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance set by the operator and/or on said prescribed dialysis dose value (Dset).
In a 138th aspect according to any one of the preceding aspects, the apparatus comprises the pre-blood pump—PBP—infusion line (52) connected at one end thereof to the blood withdrawal line in a region of the blood withdrawal line which is positioned in use upstream from the blood pump (21), in particular the blood pump (21) being active in correspondence of a segment of the blood withdrawal line (6), wherein the control unit is configured to calculate the set value for the fluid flow rate (QPBP) in the pre-blood pump—PBP—infusion line (52), which is not set by the operator, based on at least a part of the clinical prescription parameters, in particular the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance set by the operator and/or on said prescribed dialysis dose value (Dset).
In a 139th aspect according to any one of the preceding aspects, the apparatus comprises the anticoagulant infusion line (51) connected at one end thereof to the blood withdrawal line in a region of the blood withdrawal line which is positioned in use upstream from the blood pump (21), in particular the blood pump (21) being active in correspondence of a segment of the blood withdrawal line (6), wherein the control unit is configured to calculate the set value for the fluid flow rate (Qcit) in the anticoagulant infusion line (51), which is not set by the operator, based on at least a part of the clinical prescription parameters, in particular the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance set by the operator and/or on said prescribed dialysis dose value (Dset).
In a 140th aspect according to any one of the preceding aspects, the operating parameters further comprises a blood flow rate (Qb) in the extracorporeal blood circuit (17), wherein the control unit is configured to calculate the set value for the blood flow rate (Qb) in the extracorporeal blood circuit (17), which is not set by the operator, based on at least a part of the clinical prescription parameters, in particular the target value for the parameter (nNBL; CpHCO3_pat) indicative of a steady state acid-base balance set by the operator and/or on said prescribed dialysis dose value (Dset).
In a 141st aspect according to any one of the preceding aspects, the control unit (12) is configured to calculate three or more, and in particular four or more, set values of the fluid flow rates selected in the group.
In a 142nd aspect according to any one of the preceding aspects, the control unit (12) is configured to calculate the set value for a patient fluid removal rate (QPFR) from the patient.
In a 143rd aspect according to any one of the preceding aspects, said prescribed dialysis dose value (Dset) comprises a prescribed value for a flow rate or a combination of flow rates.
In a 144th aspect according to any one of the preceding aspects, said prescribed dialysis dose value (Dset) comprises a prescribed value for one selected in the group including:
In a 145th aspect according to the preceding aspect, the control unit (12) is configured to correct the selected one of the above defined doses to take into account a predilution effect, when a infusion line (29; 51; 52) is present and delivers fluid upstream from the treatment unit (2), by multiplying the dose value times a dilution factor (Fdilution), which is <then 1, as per the following formula:
Dosecorr_xxx=Fdilution×Dose_xxx(withxxx=eff, conv, dial).
In a 146th aspect according to any one of the preceding aspects, the control unit (12) is configured to control the blood pump (21) using either the entered or the calculated set value for the blood flow (Qb).
In a 147th aspect according to any one of the preceding aspects, the CRRT apparatus further comprises a graphic user interface (15) connected to said control unit (12), said control unit being configured to:
In a 148th aspect according to any one of the preceding aspects, the actuators for regulating the flow of fluid through said fluid lines comprises a pre-infusion pump (31) for regulating the flow through said pre-dilution infusion line (29) and/or a post-infusion pump (65) for regulating the flow through said post-dilution infusion line (63).
In a 149th aspect according to any one of the preceding aspects, a dialysis liquid supply line (8) is connected to the inlet of the secondary chamber (4), and the actuators for regulating the flow of fluid through said fluid lines comprises at least a dialysis fluid pump (25) for regulating the flow through said dialysis liquid supply line (8).
In a 150th aspect according to any one of the preceding aspects, the actuators for regulating the flow of fluid through said fluid lines comprises PBP infusion pump (53) for regulating the flow through said pro-blood pump—PBP—infusion line (52) and/or an anticoagulant pump (54) for regulating the flow through said anticoagulant infusion line (51).
In a 151st aspect according to any one of the preceding aspects, the actuators for regulating the flow of fluid through said fluid lines comprises a bicarbonate pump (24) for regulating the flow through said post-dilution bicarbonate infusion line (23) and/or an ion balancing pump (75) for regulating the flow through said ion balancing infusion line (74).
In a 152nd aspect according to any one of the preceding aspects, the CRRT apparatus further comprises a collection container (62) connected to an end of the effluent fluid line (13) to collect spent dialysate.
In a 153rd aspect according to any one of the preceding aspects, the CRRT apparatus further comprises a replacement container (30) of fresh fluid connected to an end of the pre-dilution infusion line (29)), in particular said container (30) being a bag containing a replacement solution.
In a 154th aspect according to any one of the preceding aspects, the CRRT apparatus further comprises an auxiliary container (64) of fresh fluid connected to an end of the post-infusion line (63), in particular said container (64) being a bag containing a replacement solution.
In a 155th aspect according to any one of the preceding aspects, the CRRT apparatus further comprises a liquid container (14) of fresh fluid connected to an end of the dialysis liquid supply line (8), in particular said container (14) being a bag containing fresh dialysis fluid.
In a 156th aspect according to any one of the preceding aspects, the CRRT apparatus further comprises a PBP container (18) of fresh fluid connected to an end of the pre-blood pump infusion line (52), in particular said container (18) being a bag containing a replacement solution.
In a 157th aspect according to any one of the preceding aspects, the CRRT apparatus further comprises a container (10) for regional anticoagulant connected to an end of the anticoagulant infusion line (51), in particular wherein said container (10) is a bag and contains citrate, and optionally citric acid.
In a 158th aspect according to any one of the preceding aspects, the CRRT apparatus further comprises a bicarbonate container (24) connected to an end of the post-dilution bicarbonate infusion line (23), in particular said container (24) being a bag containing a bicarbonate solution, optionally a concentrated bicarbonate solution.
In a 159th aspect according to any one of the preceding aspects, the CRRT apparatus further comprises an ion balancing solution container (11) connected to an end of the ion balancing infusion line (74), in particular said container (11) being a bag or a syringe containing a calcium concentrated solution.
In a 160th aspect according to any one of the preceding aspects, the CRRT apparatus further comprises one or more scales weighing one or more of said containers, in particular the apparatus comprising a corresponding scale for each respective of said containers, said one or more scales being connected to the control unit and sending to the control unit corresponding weight signals.
In a 161st aspect according to any one of the preceding aspects, the memory (16) stores one or a plurality of optimization criteria, said control unit (12) being configured to calculate the set value for the fluid flow rate/s by applying the optimization criteria.
In a 162nd aspect according to the preceding aspect, the optimization criteria comprises a first optimization criterion imposing that an emptying time of at least one among the containers (10; 18; 30; 64; 28; 11; 14) of fresh fluid and/or a filling time of the collection container (62) is substantially same as or multiple of the emptying time of one or more of the other containers of fresh fluid.
In a 163rd aspect according to any one of the preceding two aspects, the optimization criteria comprises a second optimization criterion imposing that fluid consumption through said fluid lines is minimized.
In a 164th aspect according to any one of the preceding three aspects, the optimization criteria comprises a third optimization criterion imposing that a life time of said filtration unit (2) is maximized.
In a 165th aspect according to any one of the preceding four aspects, the optimization criteria comprises a fourth optimization criterion imposes that urea clearance or dialysance of a given solute is maximized.
In a 166th aspect according to any one of the preceding five aspects, the control unit (12) is configured to allow the user selecting one or more of said criteria and calculate said at least one flow rate using said selected criteria.
In a 167th aspect according to any one of the preceding six aspects, the control unit (12) is configured to allow the user selecting one or more of said criteria and one or more of said further mathematical relations and to calculate at least three or more flow rates using said selected criteria and said selected further mathematical relations.
In a 168st aspect according to any one of the preceding aspects, the control unit (12) is configured to determine if said selected further mathematical relations are compatible or conflicting with each other and then:
In a 169th aspect according to any one of the preceding aspects, the control unit (12) is configured to store in the memory (16) the volume or weight of fluid which is contained in each container (10; 18; 30; 64; 28; 11; 14) of fresh fluid and optionally in the collection container (62).
In a 170th aspect according to the preceding aspect, said volume or weight of fluid is detected by a sensor associated to each respective container and connected to the control unit (12).
In a 171st aspect according to the preceding aspect, wherein said volume of fluid is detected based on signals associated to the corresponding pump acting on the infusion line fluidly connected to the respective container, for example based on signals from a Hall sensor associated to a peristaltic pump or based on plunger position in a syringe pump.
In a 172nd aspect according to the preceding aspect, wherein said volume of fluid is detected based on signals associated to the corresponding pump in one or more of
In a 173rd aspect according to the preceding aspect 170, wherein said sensor is a weight scale weighing at least one of said containers.
In a 174th aspect according to the preceding aspect 170, wherein said sensor is a droplet counter determining weight and/or volume based on drops count.
In a 175th aspect according to any one of the preceding aspects, a data carrier is provided comprising instructions which when executed by the control unit of an apparatus according to any one of the preceding apparatus aspects render said control unit configured to execute the respective steps described in the preceding aspects.
Aspects of the invention are shown in the attached drawings, which are provided by way of non-limiting example, wherein:
As mentioned, extracorporeal blood treatment (dialysis) may be used in patients with rapidly developing loss of kidney function, called acute renal failure or slowly worsening kidney function, called Stage 5 chronic kidney disease (or end-stage renal disease). In the following description, some embodiments of extracorporeal blood treatment apparatuses will be firstly described being suitable, or designed, principally for intensive care treatments. Citrate regional anticoagulation will be thereafter introduced followed by definition of steady state acid-base balance parameter/s. The methods to simplify and/or assist CRRT prescription on the basis of meaningful clinical parameters are thereafter described and may be implemented in any of the described embodiments as it is apparent from the following description.
Unless defined otherwise, all technical and scientific terms used have the same meaning as commonly understood by one of ordinary skill in the art.
The term ‘downstream’ refers to a position of a first component in a flow path relative to a second component wherein fluid will pass by the second component prior to the first component during normal operation. The first component can be said to be “downstream” of the second component, while the second component is “upstream” of the first component.
We define the “dialysis fluid” as the treatment fluid introduced to the second chamber of the filtration unit 2. The dialysis fluid may be on-line prepared or pre-packaged in sterile bags. Usually in CRRT apparatuses/applications the dialysis fluid, but also the replacement fluids (possibly also regional anticoagulant fluid and/or ion re-establishing solution fluid) are contained in (disposable) bags.
We define the “dialysate” or “effluent” as the fluid from the outlet from the second chamber of the filtration unit 2. Dialysate or effluent is the spent dialysis fluid, comprising the uremic toxins removed from the blood and may include ultrafiltrate fluid.
We define “regional anticoagulant” as a substance which, once mixed with extracorporeal blood, substantially prevents blood coagulation in the extracorporeal blood circuit and which is quickly metabolized by the patient, thus avoiding systemic anticoagulation.
We define “net buffer load” during the extracorporeal blood treatment (e.g., CRRT) the combination of bicarbonate generated from the metabolism of bicarbonate precursors, such as citrate and/or lactate infused into the patient (Jmet_cit; Jmet_lact), bicarbonate balance from the extracorporeal blood therapy (JHCO3_bal) which may match with net loss or net gain for the patient, and acid infusion, e.g., from citric acid content of the anticoagulant solution, when relevant. From the mathematical point of view, the general definition of net buffer load (mmol/h) used hereinafter is:
J
buffer_load
=J
met_cit
+J
HCO3_bal
+J
met_lact
−J
H+
We define “citrate dose” as the injected amount of citrate per liter of blood treated (mmol/L blood); it defines the intensity of citrate anticoagulation.
We define patient “citrate load” as the rate at which citrate is returned to the patient (mmol/h).
J
citrate_load
=J
cit_PBP
−J
cit_eff
We define “bicarbonate balance” as the net infusion or loss rate of bicarbonate in the extracorporeal blood treatment matching with the difference between the infusion rate from the dialysate and/or replacement fluids and the bicarbonate removal rate into dialysate.
J
HCO3_bal
=J
HCO3_inf
−J
HCO3_eff
We define “calcium compensation” (or calcium compensation parameter) as the relative dosage of calcium infusion to compensate for the estimated calcium loss in dialysate, expressed in percentage.
We define “total calcium concentration”, particularly in the effluent as the total amount of calcium per unit of liquid volume in the effluent, including both ionized and bound calcium.
We define “K0A” as the mass transfer-area coefficient of a filtration unit, wherein K0 is the clearance at infinite blood and dialysis fluid flow rates and A is the filtration unit surface area “K0A” is specific of a given solute and thereby changes according to the solute which is specifically considered.
In this application the term “citrate” means that the component is in form of a salt of citric acid, such as sodium, magnesium, calcium, or potassium salt thereof. The citric acid (denoted C6H8O7) is deprotonated stepwise, therefore the “citrate” include all the different forms, citrate (denoted C6H5O73−), hydrogen citrate (denoted C6H6O72−), and dihydrogen citrate (denoted C6H7O7−).
The term “citrate” or “total citrate” means the total amount of citric acid and any salts thereof, such as its sodium, magnesium, calcium, or potassium salt thereof. In other terms, “total citrate” is the sum of free citrate ions and citrate containing complexes and ion pairs.
The term “buffer agent” means bicarbonate or bicarbonate precursors such as lactate, citrate or acetate.
We define “number of degrees of freedom” as the difference between the numbers of operating flow rates to be computed minus the number of prescription parameters.
The following terms/parameters are consistently used throughout the equations provided in the following description of the detailed working of the extracorporeal blood treatment apparatus.
It is noted that values for the above constants are exemplificative. For example, patient plasma bicarbonate concentration may be set at a different level based on medical staff decision e.g., 27 mM; the same occurs with normalized net buffer load that may assume different values such as 0.15 mmol/h/kg. Further, other constants may be more (or less) precisely estimated without affecting the other part of the present description.
With reference to
At least for the reasons set forth above, CRRT systems need to exhibit specific technical features enabling the system to:
Finally, in order to ready a CRRT apparatus as soon as possible given the acute situation of a patient requiring a treatment and given the absence of advance notice of the emergency situation requiring treatment, the CRRT machine is dressed using an integrated disposable set, wherein all the lines and the filtration unit are grouped together and already properly connected in the disposable set. Further, all the fluids are contained in pre-packaged bags (dialysis fluid or replacement fluids in bags of e.g., 2, 5 or 10 litres each) or pre-packaged syringes (heparin and/or concentrated calcium replacement solution).
The apparatus 1 of
The blood passes through the primary chamber 3 of the filtration unit 2 and, through the blood return line 7, the treated blood is carried back to the patient. In the example of
After defining a direction of fluid (blood) circulation 200 (during normal use of the apparatus) from the blood withdrawal line 6 towards the filtration unit 2 and from the latter through the blood return line 7 towards the patient P, a known blood pressure sensor 48, which shall not be described in further detail, is placed immediately downstream the anticoagulant line 51. The blood circuit 17 comprises actuator/s for conveying fluid, i.e. in this particular case at least a blood pump 21 for controlling and managing the suitable blood flow Qb in the circuit. Also the blood pump 21 is generally a peristaltic pump acting either on the blood withdrawal line (as shown e.g. in
Then, the blood passes through another pressure sensor 49 controlling the correct flow within the blood circuit. After passing through the primary chamber 3 of the filtration unit 2, where the suitable exchanges of substances, molecules and fluids occur by means of a semipermeable membrane, the treated blood enters the blood return line 7, first passing through the air separator 19, commonly known as “bubble trap”, designed so as to ensure the detection and removal of air bubbles present in the blood. The treated blood getting out of the air separator 19, before being returned to the patient P passes through an air bubble sensor 55 verifying the absence of said dangerous formations within the treated blood that has to be re-introduced in the patient's blood circulation. Immediately downstream from the bubble sensor 55, the safety valve 20 (or venous clamp) is placed which, in case of alarm, can block the blood flow towards the patient. In particular, should the bubble sensor 55 detect the presence of anomalies in the blood flow, the machine through safety valve 20 would be able to block immediately the passage of blood so as to avoid any consequence to the patient. A corresponding safety valve 27 (or arterial camp) is present on the blood withdrawal line cose the patient vascular access to fully isolate the patient from the extracorporeal blood circuit in case of need. Downstream from the safety valve 20, the treated blood is then carried back to the patient P undergoing therapy. The extracorporeal blood treatment apparatus of
The apparatus is equipped with means 71 for determining at least the weight of the primary fluid container 14 and/or of the auxiliary fluid container 64 and/or of the regional anticoagulant container 10 and/or of the collection container 62. In particular, said means 71 comprises weight sensors, for instance respective scales A, B, C, D and E (for example at least an independent sensor for each fluid bag associated to the machine). In particular, there will be at least four of said scales, each pair being independent from the other, and each one measuring the respective weight of a bag. It should then be pointed out that there is a control unit or CPU 12 active (at least) on the blood circuit 17 and in particular active on the pressure sensor 48 for reading pressure values, on the blood pump 21, on the gas exchanger 46, on the other pressure sensor 49, and on the device for detecting the presence of air bubbles 55 and on the respective safety valves 20, 27. The control unit 12 has also to control the dialysis fluid circuit 32 and, in particular, shall be input with the data detected by the scales A, B, C, D and (possibly) E and, concerning the weight of the bag 14, and shall act on the pump 25, on the selector 59, on the pressure sensor 60, then on the dialysate pump 26 and shall eventually receive the data detected by the scale A whose function is to determine the weight of the collection container 62. The control unit 12 shall also at on the infusion line 63 checking the weight of the auxiliary container 64 (checked by the scale C) and will be able to control both the infusion pump 65 and the other selector 70. The control unit 12 shall also act on the anticoagulant line 51 detecting the weight of the anticoagulant fluid container 10 by means of the scale B and suitably controlling the anticoagulant pump 54 according to the treatments to be carried out as below detailed and explained. As apparent, a regional anticoagulation system is implemented in the apparatus 1 of
The control unit 12 is also connected to a memory 16 and to user interface 15, for instance a graphic user interface, which receives operator's inputs and displays the apparatus outputs. For instance, the graphic user interface 15 may include a touch screen, a display screen and/or hard keys for entering user's inputs or a combination thereof.
A regional anticoagulation system comprises a source of regional anticoagulant 10, e.g., a container or a bag containing at least a substance having an anticoagulant effect. For example, citrate, in the form of pure sodium citrate (Na3 citrate) or mixture of sodium citrate and citric acid are used for blood anticoagulation purpose. Alternatively pure citric acid may be used as anticoagulant. Indeed, citrate has a high affinity for calcium in creating complexes and several steps of the coagulation cascade are dependent on blood (ionized) calcium. A proper decrease of ionized calcium concentration in the presence of citrate inactivates the coagulation cascade.
Normal plasma includes about 1.1 to 1.3 mmol/l of ionized calcium, 0.1-0.2 mmol/l of complexed calcium and 0.9 to 1.2 mmol/l of protein-bound calcium. In order to achieve proper anticoagulation effects, general guidelines are to adjust citrate amount/dose as to reach an ionized calcium concentration of 0.20 to 0.35 mmol/l in the extracorporeal blood circuit after citrate infusion. Plasma with citrate addition for anticoagulation purposes would include (as an average) about 0.3 mmol/l of ionized calcium, 1.8 mmol/l of complexed calcium (mainly Ca3 citrate2) and 0.2 mmol/l of protein-bound calcium. During RCA, intensity of anticoagulation can be adjusted via the amount of infused citrate. Post-filtration unit ionized calcium concentration is commonly used as key parameter (target in the 0.20-0.35 mmol/l range) and is measured e.g., with blood gas analyzer.
The regional anticoagulation system is arranged to deliver the regional anticoagulant at a delivery point 50 in the extracorporeal blood circuit 17. Citrate infusion is preferably administered close to an access end of the blood withdrawal line 6 to get full anticoagulation of the extracorporeal blood circuit 17. In general the delivery point 50 is located upstream the blood pump 21; however, it is not excluded that the delivery point 50 is located in the blood withdrawal line 6 downstream the blood pump. Alternatively, or in combination, the delivery point 50 for citrate may be the inlet of the filtration unit 2. In this latter configuration, the dialysis fluid contains citrate in an amount sufficient to achieve ionized cadium level around 0.25-0.35 mmol/l in blood circuit downstream the dialyzer. Citrate may be added to the treatment fluid flowing along the supply line 8 using a corresponding concentrate bag/container in case the dialysis fluid is on-line prepared as in current apparatuses for chronic treatment. Alternatively, particularly in case of CRRT apparatuses, the source 14 for dialysis fluid is a container/bag including the proper citrate concentration or content.
Commercial citrate solutions are generally packed in respective plastic bags (sources 10) and can be split between physiologic and concentrated solutions. Physiologic citrate solutions are solutions having sodium concentration about 140 mmol/l, such as Baxter PrismoCitrate 10/2 (with 10 mmol/l Nacitrate and 2 mmol/l citric acid) and Baxter RegioCit 180 (with 18 mmol/l Nacitrate). Concentrated citrate solutions are for example, ACD-A (Anticoagulant Citrate Dextrose Solution) from Biomet mix of sodium citrate (75 mmol/l), citric acid (38 mmol/l) and glucose; and Citrate 4% from Fresenius: citrate 136 mmol/l.
When citrate is infused into the blood withdrawal line 6 close to the patient vascular access, blood pump speed is automatically adjusted as to take the operator set blood flow rate from access site (blood pump speed=k*((Qb+Qcit), wherein Qb is the set (or calculated) blood flow rate—desired at the access site and Qcit is the citrate infusion flow rate). Citrate amount is prescribed through the ‘Citrate Dose’ parameter (Da) which is the amount of citrate per liter of blood treated (mmol/l blood). Notably, citrate dose does not match with citrate concentration in the diluted blood reaching the filtration unit. The concept is rather to provide for an amount of citrate in proportion to the amount of calcium to be chelated. The set of the citrate pump 54 is:
wherein
Citrate infusion is delivered with a dosage aimed to maintain ionized calcium level around 0.25-0.35 mmol/l in blood circuit downstream the dialyzer. Typically, citrate dose is included in the range 1.5 to 6.0 mmol/l-of-blood. The most common range is 2 to 4 mmol/L-of-blood. Citrate dose guideline of 3.0 mmol/L-of-blood is globally followed.
Ionized calcium and citrate complexes are rather small molecules which are easily transferred through the filtration unit 2. Loss rates are basically dependent on flow rates, filter efficiency with respect to small molecules and solute concentrations. While about half of the total calcium is not available to mass transfer during standard anticoagulation (since it is protein-bound), about 90% of total calcium becomes available during citrate anticoagulation. Therefore, citrate regional anticoagulation combined with the use of calcium free dialysis and/or replacement fluids implies significant calcium losses to dialysate. In extracorporeal blood treatments with RCA, calcium infusion is required to balance calcium losses to dialysate. During RCA, calcium infusion is adjusted to keep patient systemic ionized calcium in the normal range (e.g., 1.0-1.2 mmol/l).
Therefore, the regional anticoagulation system of the apparatus 1 includes a source of ion balancing solution 11, which is reinfused in the blood, either in the return line 7, in particular close to the venous vascular access, or directly into the patient P (infusion into central catheter, which is recommended). The ion balancing solution 11 is contained in a vessel e.g., a syringe, a container or a bag; the regional anticoagulation system of the apparatus 1 comprises a ion replacement infusion line 74 and a corresponding ion replacement pump 75 to drive delivery of a proper ion replacement infusion rate Qca.
In an implementation, the ion balancing solution flow rate is kept proportional to the estimated calcium loss rate in dialysate. For example it is computed by the apparatus control unit through the equation (calcium flow rate mathematical relation):
Where CaComp is a calcium compensation parameter, Qca is the ion balancing solution flow rate (ml/h), Jca is the estimated calcium loss rate in the dialysate (mmol/h), Cca is calcium concentration of the ion balancing solution (mmol/l), Qrep.post is the post-dilution replacement flow rate (ml/h), Cca_rep.post is calcium concentration of the replacement solution in post-dilution (mmol/l), QHCO3 is the fluid flow rate (ml/h) through the post-dilution bicarbonate infusion line 23, and Cca_HCO3 is the calcium concentration in the bicarbonate container. Calcium compensation is the user-controllable setting, which might be set by the operator generally in a range between 5% and 200%.
Notably the above equation takes into account a post replacement solution including calcium, as well as bicarbonate infusion also including calcium. In case no calcium is in the post replacement solution (or no replacement solution is used) the second term of the equation should be disregarded (equal to zero). In case no calcium is in the bicarbonate replacement solution (or no bicarbonate solution is used) the third term of the equation should be disregarded (equal to zero).
The calcium flow rate mathematical relation is also used by the control unit 12 to determine the ion re-establishing flow rate Qca based on known (input) calcium concentration in the various post infused solutions. Further, it is assumed that no calcium is infused upstream the filtration unit 2 to avoid undesired coagulation effects (in this respect the anticoagulant solution does not contain any calcium and the pre-dilution infusion line 67 is absent or the replacement solution pre-infused is calcium free). Further, the ion compensating parameter is part of the prescription as well. The post infusion flow rates, namely Qrep.post and QHCO3 are operating parameter and the control unit 12 determines them based on the prescription parameters and apparatus configuration. Also Jca is estimated, for example as disclosed in the mentioned US866882582 application.
Alternatively, the medical staff may provide a ‘calcium dose’ Dca in terms of calcium concentration in the effluent (mmol/l). The ion balancing solution flow rate Qca is calculated based on the set calcium dose taking into account calcium concentration of the ion balancing solution, calcium concentration of the replacement solution and estimated calcium concentration in blood at the outlet of the filtration unit 2.
Indeed, as to dialysis fluid (and replacement solution), they are generally calcium free to prevent transferring ionized calcium to blood. Moreover, the dialysis and/or replacement fluids may have adapted buffer content due to citrate metabolism and adapted sodium if concentrated citrate solution (hypertonic) is used.
As to the buffer agent, since RCA has complex impact on acid-base balance equilibrium due to a significant fraction of citrate returned to patient (citrate is metabolized into bicarbonate), when assisting prescription, the control unit 12 would require input of a steady state acid-base balance target to be achieved. Indeed, blood returned to the patient contains a significant concentration of citrate-calcium complexes. These complexes are (quickly) metabolized in liver, skeletal muscles, kidney releasing calcium in the blood stream, thus preventing systemic anticoagulation to develop; the citrate metabolism produces bicarbonate (3 moles HCO3− for 1 mole citrate).
In this respect, the dialysis fluid may contain no buffer agent, e.g., no bicarbonate. A buffer agent from a source/container/bag 64 may be infused into the blood return line 7 via a suitable buffer agent supply line 63, 69, 66 and the corresponding buffer agent pump 65. Alternatively or in combination, to allow for acid-balance additional control, the apparatus 1 might also be designed to vary buffer balance of the extracorporeal blood circuit in an easy and controlled way via the possibility to set dialysis fluid (low) buffer concentration and/or to use source bags 14, 64 with different buffer concentration, e.g., in the range 15 to 25 mmol/l (and up to 40 mmol/l and/or down to 0 mmol/l) for bicarbonate. As described, a specifically designed bicarbonate solution may be post-infused to allow for acid-base balance additional control (see e.g.,
As mentioned, citrate accumulation in the patient may correlate with hypocalcemia, metabolic acidosis (low bicarbonate production due to poor metabolism) or metabolic alkalosis (excessive bicarbonate production subsequent to high citrate load). As citrate measurement is not commonly available at the hospital, ratio of total calcium to ionized calcium is used as indicator, namely values below 2.5 are considered as normal (normal value below 2.0) and values above 2.5 indicate low ionized calcium concentration with respect to total calcium, possibly due to the presence of a significant systemic concentration of citrate. However, this monitoring is considered an insufficient measure, particularly in treatment involving relevant risks of acid/base unbalance, such as in RCA with ‘large’ flow rates, such as certain SCUF treatments.
The embodiment of
The embodiment of
Embodiment of
The embodiment of
The embodiment of
Further, the two infusion lines 51 and 52 infusing fluids pre-blood-pump, may be substituted by a single line, used for citrate in case of regional anticoagulation, or for PBP replacement fluid in case of no or system anticoagulation.
Finally, it is noted that in case any line is missing in a specific circuit configuration, the corresponding flow rate may be omitted in any of the following formula/mathematical relations (or its value set to zero).
The following equations for flow rates express the relations between the flow rates which are used in the detailed description. These equations are stored in the memory 16 of the apparatus. When necessary, the control unit 12 makes use of the following equations to determine the operative parameters (as explained in the following sections).
The plasma flow rate is function of blood flow rate as follows:
Qp=Q
b·(1−Hct) (Eq. 3)
The plasma water flow rate is function of blood flow rate as follows:
Qpw=Qp·F
p
=Q
b(1−Hct)·Fp (Eq. 4)
The plasma water flow rate at the filter inlet is:
Qpw
inlet
=Qpw+Q
cit
+Q
syr
+Q
PBP
+Q
rep.pre
=Q
b·(1−Hct)·Fp+Qcit+QPBP+Qrep.pre (Eq. 5)
The blood water flow rate is function of blood flow rate as follows:
Qbw=Q
b·[(1−Hct)·Fp+Hct·Frbc] (Eq. 6)
The blood water flow rate at the filter inlet is:
Qbw
inlet
=Q
bw
+Q
cit
+Q
syr
+Q
PBP
+Q
rep.pre=
Q
b·[(1−HCt)·Fp+HCt·Frbc]+Qcit+QPBP+Qrep.pre (Eq. 7)
The ultrafiltration rate in the filtration unit is:
Q
fil
=Q
PBP
+Q
cit
+Q
syr
+Q
rep.pre
+Q
rep.post
+Q
HCO3
+Q
PFR
+Q
ca (Eq. 8)
In case one single infusion line 63 (as in
Q
rep.pre
=PRE·Q
rep
Q
rep=(Qrep.pre+Qrep.post) (Eq. 9)
The effluent flow rate is:
Q
eff
=Q
PBP
+Q
cit
+Q
syr
+Q
dial
+Q
rep.pre
+Q
rep.post
+Q
HCO3
+Q
PFR
+Q
ca
=Q
dial
+Q
fil (Eq. 10)
Clinical prescription parameters are the parameters that the CRRT apparatus requires from the medical staff when initiating or updating treatment prescription on a specific patient. The apparatus may either request the physician to input the prescription parameter or provide a suggested value to be confirmed or updated. Prescription parameters to be confirmedl updated may be read from patient cards or similar supports.
Purpose of the “assisted prescription” process is to operate from prescription parameters being fully meaningful from the clinical perspective; selected prescription parameters of interest are listed in next table.
Not all the above mentioned clinical prescription parameters are necessary/required, but their relevance depends on selected treatment options and medical staff preferences.
For example, blood flow rate listed in the table may be used as prescription parameter (set by medical staff) or as operating parameters (set by the system algorithm) according to the customer preference as hereinafter described.
Citrate dose and calcium compensation are relevant in case of regional anticoagulation treatments and not necessary in case of no or systemic anticoagulation.
Patient fluid removal rate may be entered as a prescription or, alternatively, may be calculated by the control unit.
In general, CRRT dose is the ‘running’ dose which has to be derived from the clinical target (20 to 25 ml/kg/h according to KDIGO guidelines) corrected for system down times; this leads to a recommended running dose in the 25-30 ml/kg/h range. The CRRT dose is further explained in the following paragraph.
As previously indicated, citrate dose controls the intensity of anticoagulation; it should be adjusted as to decrease ionized calcium concentration in the extracorporeal blood circuit down to the 0.2-0.35 mM range. In parallel, calcium compensation controls the balancing level of calcium losses relatively to a computed default loss rate; alternatively to a percentage, calcium balancing may be prescribed as a concentration of calcium in effluent (calcium dose Dca).
Steady state acid-base balance target is either defined as a steady state patient bicarbonate concentration (requiring an assumption on nNBL), or as normalized Net Buffer Load (requiring an assumption on bicarbonate concentration). Second option is normally preferred. At steady state, nNBL is expected to balance the protons (H+) generation rate from patient metabolism. The steady state acid-base balance target is further discussed in the following paragraphs. Patient fluid removal prescription directly derives from the analysis of the patient fluid balance, considering all patient's fluid inputs and outputs, as well as the desired correction of patient's fluid status. It is clear that setting the patient fluid removal rate may be preferred; however, the setting of another fluid flow rate may allow to determine patient fluid removal rate as a consequence (e.g., setting effluent flow rate and using Eq. 10 having knowledge of the infusion flow rates and dialysis flow rate).
Blood flow rate is not expected to have any strong clinical background aside some technical considerations on the patient's vascular access. If chosen as prescription parameter, the medical prescription may either provide a desired set value or simply define lower and/or upper limits(s) of the blood flow rate setting range.
In the present specification, CRRT dose refers primarily to a flow rate or to a combination of flow rates (expressed then in ml/h). It is however noted that an additional definition of treatment dose in CRRT is expressed in ml/kg/h, meaning the normalisation of a flow rate (or combination of flow rates) to patient body weight (BW). Particularly for infants, literature CRRT dose also refers to a treatment dose normalised to patient Body Surface Area (BSA).
Dose (aside from its ‘normalisation’ to patient size) can be defined as a combination of the flow rates in the most general way, with following examples:
All below expressions of Dose are not normalised to patient size (body weight BW or patient surface area PA); expressions of normalised dose (NDose) can be directly expressed as:
For example, one of the following magnitudes may be used as dose:
D
conv
=Q
PBP
+Q
cit
+Q
syr
+Q
rep.pre
+Q
rep.post
+Q
PFR
+Q
ca
+C
HCO3, or
D
conv
=Q
fil
of course, in case one or more lines are absent, the corresponding flow rate term/s may be absent from the definition or the value/s set to 0;
In the course of the following description reference will be made to the above dose definitions which are relating to doses not normalized to patient body weight (BW) or patient surface area (BSA). Of course the same principles and formulas below described could be normalized to body weight or patient surface area by dividing the dose value by either body weight BW or surface area BSA. The examples at the end of the description comprise normalized CRRT doses and the patient weight
Furthermore, the above defined doses could be corrected to take into account the predilution effect, when a fluid replacement line is present upstream the treatment unit, such as lines 51 and 67 in the enclosed drawings. Each of the above defined doses could be corrected multiplying the dose value times a dilution factor Fdilution;
Dosecorr_xxx=Fdilution·Dxxx(withxxx=eff, conv, dial, etc);
The dilution factor Fdilution may be defined according to one of the following:
Where Qcit and/or QPBP and/or Qrep.pre and/or Qsyr in above equations is absent or negligible, the corresponding term may be cancelled (or set to 0). In the entire application, whenever a term in a formula is negligible (usually this applies to syringe flow rate, but not exclusively to it, the term may be neglected, i.e., its value considered 0 or the term removed.
In practice, the effluent dose corrected for the predilution effect would be: Dosecorr_eff=Fdilution×Deff.
Fdilution factor shall be selected according to the solute distribution and ability to move through red blood cells membrane (example: creatinine with slow diffusion through red blood cells=>plasma dilution factor).
For example, in case the urea dose (Durea) is assumed to be more or less identical to effluent flow rate and as urea is distributed in whole blood and can transfer quickly through the red blood cells membrane, the correction factor to consider for predilution shall refer to whole blood. Accordingly:
More sophisticated equations can provide for a more accurate estimate of urea clearance (Kurea) than Qeff (as previously indicated in Eq. 11 and 12), especially when operating with large flow rates or small filters (paediatric conditions).
Net buffer load during extracorporeal therapies (Jbuffer_load) is defined as the combination of (one or more of):
From the mathematical point of view, the general definition of net buffer load is:
J
buffer_load
=J
met_cit
+J
HCO3
(+Jmet_lact)−JH+ (Eq. 17)
By convention, net buffer load is positive in the case extracorporeal blood therapy provides for a net gain in buffer/bicarbonate to the patient, and negative in the case of loss in buffer.
From a physiologic perspective, the extracorporeal blood therapy is expected to provide for a net buffer gain to the patient, as to balance the metabolic production of protons (proteins metabolism). However, a net buffer loss may be desirable in the scenario where the patient initiates the therapy in the situation of (severe) metabolic alkalosis.
Buffer balance parameter is derived from a modelling of one or more of:
Set buffer balance target does not match with the current buffer balance of the CRRT running therapy (which would require specific knowledge of current patient levels for citrate and bicarbonate), but with the (normalized) Net Buffer Load expected at a steady state where patient bicarbonate would stabilize at e.g., 25 mM.
Acid-base steady state is established slowly and measurable changes are commonly present after 24 hours; two days appear as a reasonable minimum to consider that acid-base status is reaching steady state in the context of CRRT. In the framework of the buffer balance analysis here introduced, acid-base balance steady state is reached when:
Citrate load is defined as the net infusion rate of citrate to the patient and it matches with the difference between the citrate infusion rate from the pre-blood-pump anticoagulant circuit (Jcit_PBP) and the citrate removal rate into dialysate (Jcit_dial), namely with the difference between citrate infusion in the blood circuit and citrate losses through dialyzer/dialysate.
From the mathematical point of view, below equations are directed to the computation of the amount of citrate returned to the patient (citrate load) which is relevant to the acid-base balance prescription during RCA.
The definition of patient citrate load is:
J
citrate_load
=J
cit_PBP
−J
cit_dial (Eq. 18)
Computation of citrate infusion can be expressed in two ways, according to the definition of citrate dose (Dcit).
From the mathematical point of view, the definition of citrate infusion rate is:
J
cit_PBP
=Q
cit
·J
cit_PBP
=D
cit
·Q
b (Eq. 19)
Citric acid and citrate forms are considered in the same way in this approach.
Removal rate of citrate into the dialysate is expressed from the definition of filter clearance for the citrate-calcium complexes (Kcit) and the citrate concentration (in plasma water) at the filter inlet.
From the mathematical point of view, the definition of citrate removal to effluent is:
J
cit_dial
=K
cit
·Cpw
cit_inlet (Eq. 20)
The hypotheses for modelling the citrate mass transfer in the extracorporeal blood circuit includes the assumptions that citrate is distributed in plasma (and not in red blood cells), that CRRT filter citrate clearance is computed also based on citrate concentration in plasma water for mass transfer computations, that consideration is taken of patient citrate metabolism and non-zero steady state citrate concentration at blood access and that patient citrate clearance is proportional to body weight.
The definition of plasma water flow rate at filter inlet is the following:
Q
pw
=Q
pw
+Q
cit(+Qsyr+QPBP)+Qrep.pre=
Q
b·(1−Hct)·Fp+Qcit(+Qsyr+QPBP)+QPBP+Qrep.pre (Eq. 5)
Here (and in the following) it is assumed that no pre-blood-pump infusion line other than (citrate) anticoagulant line 51 is present and that no heparin is used/injected since RCA is provided (i.e., no PBP replacement fluid and no syringe flow rate are considered—the terms are included between brackets for the explained reason).
The equations (equations 21) for computation of citrate clearance in CRRT with non-zero dialysis fluid and filtration flow rates are as follows:
It is noted that citrate mass transfer parameters used for computation of above removal rate are known and constant values depending on the selected dialyzer.
For example, the following table reports the values for some used Baxter Prismaflex sets:
Simpler equations might be used with lower accuracy. For example, Kcit may be assumed equivalent to effluent flow rate Qeff.
Plasma water citrate concentration at filter inlet (Cpwcit_inlet) can be defined considering or not an increase of patient citrate concentration.
Simple and rough estimate will consider that patient citrate concentration remains negligible all along the therapy (see next paragraph), however, more accurate approach needs to estimate the increase of patient systemic citrate concentration (Cpcit_pat) via an estimate of the patient citrate metabolic clearance (Kcit_met)—see below. Indeed, during an RCA treatment, citrate concentration at the blood access is never zero as some citrate accumulates in the patient. This accumulation should be taken into consideration to avoid bias of about 10% (in case of neglecting). It requires the knowledge of the citrate metabolism rate (Kcit_met) in liver and muscles of the patient that can vary in a wide range and significantly bias the final estimation. However it could be relevant to consider a ‘minimum’ accumulation that occurs for a patient having a ‘normal’ citrate metabolism. In this respect, patient citrate concentration is computed at steady state, assuming a typical metabolic clearance value of (about) 700 ml/min (from literature). Although not described in literature, patient citrate clearance is assumed as proportional to body weight.
The expression of patient systemic citrate concentration at steady state is the following:
According to the above, estimation of patient citrate metabolic clearance (ml/min) is:
The expression of citrate plasma water concentration at filter inlet is as follows:
Qp·Cp
cit
+J
cit
=QPW
inlet
·Cpw
cit_inlet (Eq. 24)
Combination of above Equation 18, Equation 20, Equation 22 and Equation 24 allows eliminating citrate concentration parameters and expressing patient citrate load as a function of flow rates and clearances.
The above citrate load mathematical relation is used in the context of the present application to relate the buffer load parameter (which depends on citrate load) with the citrate dose, the blood flow, the metabolic clearance and citrate clearance (depending on respective flow rates), as well as plasma flow rate and plasma water flow rate at filtration unit inlet.
According to previously described main variant, the increase of patient systemic citrate concentration (Cpcit_pat) subsequent to citrate anticoagulation is considered and estimated through the equations 22 and 23. This choice leads to the above reported equation 25 for citrate load.
A simpler alternative to this formulation, is to neglect changes in the patient systemic citrate concentration and to take it as a constant, for example zero. Equation 22 and Equation 23 are consequently not used according to this alternative. In the case where patient citrate systemic concentration is assumed as zero (Cpcit_pat=0), Equation 24 and Equation 25 turn into following equations Equation 24′ and Equation 25′:
Bicarbonate balance is defined as the net infusion or loss rate of bicarbonate in the extracorporeal blood treatment; it matches with the difference between the infusion rate from the dialysis and/or all replacement fluids (JHCO3_inf) and the bicarbonate removal rate into effluent (JHCO3_effl).
The definition of bicarbonate balance rate is the following:
J
HCO3_bal
=J
HCO3_inf
−J
HCO3_eff (Eq. 26)
The hypotheses for modelling the bicarbonate mass transfer in the extracorporeal blood circuit includes the assumptions that bicarbonate is distributed in both plasma and red blood cells, that bicarbonate concentration at blood access CpHCO3_pat0 is fixed (e.g., equal to 25 mM); of course, a different (fixed) value for bicarbonate concentration at blood access may be used.
Other assumptions include that the citrate solution is bicarbonate free and no other pre-blood-pump infusion with bicarbonate is present (in the reverse case, the bicarbonate content/concentration is to be taken into consideration in the bicarbonate balance, namely Qcit·CHCO3
J
HCO3_inf
=Q
dial
·C
HCO3
+Q
cit
·C
HCO3
+Q
PBP
·C
HCO3
+Q
rep.pre
·C
HCO3
+Q
rep.post·
C
HCO3
+Q
HCO3
·C
HCO3
(Eq. 27)
In case bicarbonate is in the calcium replacement infusion line 74 (unlikely due to potential risks of precipitation), then a term Qca·CHCO3
Equations of bicarbonate removal to dialysate are very similar to those of citrate; however, they differ for the fact that bicarbonate is present in the dialysis fluid, that the value of mass transfer parameter (K0A) is different and that a fixed value is considered for patient systemic bicarbonate. Clearly, in case citrate was present in the dialysis fluid, the corresponding citrate load/balance may take into consideration such dialysis fluid citrate concentration in the corresponding equations for citrate and in the same way as below indicated for bicarbonate.
The definition of bicarbonate removal to dialysate is the following:
J
HCO3_eff
=Q
dial
·C
HCO3
+K
HCO3·(CpwHCO3_inlet−CHCO3_dial)+Qfil·CHCO3_dial (Eq. 28)
Opposite to citrate, bicarbonate is easily transferred between red blood cells and plasma; whole blood water is thus considered for the computation of mass transfer to dialysate. Moreover, CRRT filter diffusive mass transfer coefficient of bicarbonate is taken identical to urea on the basis of their respective molecular weight (61 vs 60 g/mole). Sieving coefficient is taken as 1.
A constant physiological value of bicarbonate at blood access is considered.
The definition of blood water flow rate at filter inlet is as follows:
Qbw
inlet
=Q
bw
+Q
cit
+Q
syr
+Q
PBP
+Q
rep.pre=
Q
b·[(1−Hct)·Fp+Hct·Frbc]+Qcit+Qsyr+QPBP+Qrep.pre (Eq. 7)
The equations for computation of bicarbonate clearance in CRRT with non-zero dialysis fluid and filtration rates are similar to those for citrate; however, for the reasons above stated, mass transfer coefficients SC and K0A are different and the flow rate considered on the blood circuit is whole blood water flow (Qbw), instead of plasma water flow (Qpw). Indeed, bicarbonate is distributed in both plasma and red blood cells with the assumption of non-hindered transfer leading to the consideration of total blood water flow rate for the clearance estimate. The equations (equations 29) for computation of citrate clearance in CRRT with non-zero dialysis fluid and filtration rates areas follows:
It is noted that bicarbonate mass transfer parameters used for computation of above removal rate are known and constant values depending on the selected dialyzer.
For example, the following table reports the values for some used Baxter Prismaflex sets:
Alternatively to the complexity of the above equations (Eq. 29), a reasonable approximation of bicarbonate clearance in most circumstances is given by below equation for simplified estimate of filter bicarbonate clearance:
K
HCO3
=Q
eff (Eq. 30)
The plasma water concentration at filter inlet is derived from the set of below equations 31, namely:
From above equations, the expression of bicarbonate plasma water concentration at filter inlet is:
Lactate balance is defined as the net infusion or loss rate of lactate in the extracorporeal blood treatment; it matches with the difference between the infusion rate from the dialysate and/or replacement fluids (Jlact_inf) and the lactate removal rate into dialysate (Jlact_dial).
Lactate can be used as an alternative buffer to bicarbonate with the benefit of getting more stable solutions. Lactate based dialysis fluid is well known in dialysis; for example, it is used in the home dialysis version of the System One device from NxStage. Furthermore, lactate is also present in a certain number of bicarbonate solutions in the form of lactic acid as to control pH and solution stability. This is the case for the Baxter Hemosol/PrismaSol CRRT solutions range having 3 mM lactic acid. Similarly to citrate, lactate is quickly metabolized into bicarbonate when infused to the patient, with amole per mole conversion rate. Lactate may be modelled in the very same way as bicarbonate, assuming the patient steady state plasma lactate concentration is about 1.5 mM.
Lactate clearance may be assumed identical to urea clearance, even though lactate molecular weight is about double of urea (112 vs 60 g/mole). However, clearance estimate error is minimal in the CRRT context where flow rates are the primary limiting factor. Of course, a more accurate estimate might be used, e.g. using the power dependence of K0A on solute molecular weight (meaning possible to derive K0A_lactate from known K0A on Urea, creatinine, vitamin B12, inulin).
The hypotheses for modelling of lactate mass transfer in the extracorporeal blood circuit include the assumptions that lactate is distributed in plasma and red blood cells and that CRRT filtration unit lactate clearance is identical to urea clearance. Further, patient steady state plasma lactate concentration at blood access is assumed fixed at 1.5 mM; obviously a different fixed value may be assumed and used. Lactate mass balance in the extracorporeal blood circuit is computed with similar equations to bicarbonate considering metabolism of lactate load leading to 1 mole of bicarbonate per mole of lactate.
Mass transfer equations for lactate are as follows. The definition of lactate balance rate is the following:
J
lact_bal
=J
lact_inf
−J
lact_eff (Eq. 33)
Computation of lactate infusion rate is based on knowledge of the fluid composition (i.e. known lactate concentration); here it is assumed that no bicarbonate concentrate solution is infused/no lactate is present in the bicarbonate concentrate solution (otherwise, the terms QHCO3·Clact.HCO3 is to be considered); the same occurs for pre-blood-pump infusions.
J
lact_inf
=Q
dial
·C
lact_dial
+Q
rep.pre
·C
lact
+Q
rep.post
·C
lact
(Eq. 34)
Fluid composition (i.e., lactate concentration and/or replacement fluid prescription) may be entered by the physician or read through e.g., a reader of the dialysis apparatus.
The definition of lactate removal to dialysate is the following:
J
lact_eff
=Q
dial
·C
lact_dial
+K
lact·(Cpwlact_inlet−Clact_dial)+Qfil·Clact_dial (Eq. 35)
Lactate is easily transferred between red blood cells and plasma; whole blood water is thus considered for the computation of mass transfer to dialysate. Moreover, CRRT filter diffusive mass transfer coefficient of bicarbonate is taken identical to urea. Sieving coefficient is taken as 1.
Lactate clearance (Klact) is considered equal to bicarbonate clearance (KHCO3) and therefore the control unit calculates it in the same way with same equations previously presented. The expression of lactate plasma water concentration at filter inlet is:
Net patient buffer load is defined in relation to citrate infusion rate to patient (namely, citrate load) and bicarbonate generation. To achieve this target, the hypotheses on citrate metabolism include the following assumptions: metabolism of citrate load leads to 3 moles of bicarbonate per mole of citrate and Net Buffer Load (NBL) may be reduced by the rate of acid infusion, such as citric acid. The expression of bicarbonate generation rate from citrate metabolism (at steady state) is the following:
J
met_cit=3·Jcit_load (Eq. 37)
The expression referring to acid infusion rate is as follows:
J
H+=3·Jcitric_acid=3·Qcit·Ccit_PBP (Eq. 38)
Combination of Equation 17, Equation 37 and Equation 38 leads to the expression for the net buffer load as a function of citrate load and bicarbonate balance:
J
buffer_load=3·Jcit_load+JHCO3_bal−3·Jcitric_acid (Eq. 39)
It is remarked that the expression of Jcitric_acid is given in Equation 25 (or simplified Eq. 25′), while full expression of JHCO3_bal is to be derived from Equation 26, Equation 27, Equation 28, Equation 29 (or simplified Eq. 30) and Equation 32. Jcitric_acid is to be derived from Equation 38.
From a therapy perspective, net buffer load should be positive as to neutralize the proton (H+) generation rate GH+ from metabolism. Literature report typical GH+ values of about 1 mmol/day/kg, or 0.04 mmol/h/kg. Production of protons from metabolism is however strongly dependent on protein catabolism.
In case lactate is taken into consideration (optional), the expression for the net buffer load as a function of citrate load, lactate balance and bicarbonate balance becomes:
J
buffer_load=3·Jcit_load+JHCO3_bal+Jlact_bal−3·Jcitric_acid (Eq. 40)
In this case, in addition to mentioned equations for Jcitric_acid, JHCO3_bal and Jcitric_acid, the equations for Jcit_bal are required, namely Equation 33, Equation 34, Equation 35, Equation 29—if lactate clearance Klact is considered equal to bicarbonate clearance KHCO3—(or corresponding equation for lactate clearance, or simplification Klact=Qeff) and Equation 36.
The apparatus control unit is configured to receive a steady state acid-base balance target, namely a steady state acid-base balance prescription set value before the start of the treatment. This additional prescription value influences various flow rates to be determined by the control unit 12. Indeed, the definition for the steady state acid-base balance target depends on almost all operating parameters and other prescription parameters (as well as on system configuration).
As previously indicated, the steady state acid-base balance prescription may be specified either as:
At steady state, nNBL is expected to balance the protons (H+) generation rate from patient metabolism.
nNBL
The control unit 12 of the apparatus for extracorporeal blood treatment allow the operator to enter a parameter Ubuffer_load/BW) indicative of a steady state acid-base (or buffer) balance in the blood of the patient who has to undergo the CRRT blood treatment. This parameter defines a quantitative information on the intensity of the therapy with respect to the net patient buffer (bicarbonate) gain or loss. This parameter is of high and peculiar interest in the complex cases of citrate anticoagulation, but it remains also relevant to any extracorporeal dialysis therapy (run with systemic or no anticoagulation). In more detail, the control unit 12 receives the net buffer load at the apparatus setting (i.e., before the CRRT treatment is started).
The definition of normalized net buffer load (nNBL) is the following:
nNBL is chosen as the indicative parameter of acid-base balance level at steady state, and is expressed as amount of buffer infused per unit of time and per patient kg (mmol/h/kg).
In this respect, it is noted that Jbuffer_load is linked to several other flow rates through the equations previously indicated. Indeed, Jbuffer_load and consequently NBL or nNBL, is defined based on equations 17, 26, 27, 28 (or 26′ combination of Eq. 26, 27 and 28), 29 (or 30), 32, 38; in case lactate is present definition is additionally based on equations 29 (or 30), 33, 34, 35 and 36. All these equations are function of one or more other flow rates of the CRRT apparatus configuration. Therefore, imposing a set value for the steady state acid base balance prescription generate a constraint between the various fluid flow rates and consequently influences the operating flow rates of the apparatus. By solving the mentioned equations, the apparatus control unit 12 may derive corresponding flow rates of operating parameters matching with the prescription (as apparent from the following detailed description).
Notably, review of published clinical data on CRRT with RCA at steady state has shown good correlation of this nNBL parameter with both steady state patient bicarbonate and base excess. Therefore, instead of using the (normalized) net buffer load as above defined, the buffer balance parameter could be expressed as the steady state bicarbonate concentration, once assuming a ‘default’ value for the normalized net buffer load (nNBL); see further paragraph in this respect.
In the previously described embodiment, nNBL matches with the value of buffer balance when the patient reaches the assumed bicarbonate level (e.g; 25 mM)=>nNBL25). If nNBL25 matches with the protons generation rate (G), then steady state is reached and patient will stabilize at the assumed HCO3 level (25 mM). Alternatively, if nNBL25 is larger than the protons generation rate, patient bicarbonate will increase up to Ceq such as nNBLCeq matches with the (current) protons generation rate. In case nNBL25 is lower than GH+, then patient bicarbonate will stabilize at a lower value than the assumed level.
Though the parameter indicative of a steady state acid-base (or buffer) balance in the blood of the patient has been described as normalized over patient weigh, it is also possible to normalize the parameter over patient surface or over another patient-related variable. Of course, and even if it is not considered the best approach, the control unit 12 may also receive the Net Buffer Load (mmol/h) without any normalization.
Variant with steady state HCO3 Indicator—CpHCO3_pat
Patient bicarbonate concentration (CpHCO3_pat) could be alternatively taken as the indicative parameter of steady state acid-base equilibrium, providing that the (desirable/targeted) nNBL level has been chosen. In this scenario, previous equations may be re-arranged as to express the patient steady state bicarbonate concentration as a function of a predefined nNBL level, for example nNBL0=0.1 mmol/h/kg. Citrate equations, namely equations 18-25, 24′ and 25′, remain unchanged.
Differently, bicarbonate equations require some rearrangement. In more detail, expression of steady state patient bicarbonate (rearrangement of Equation 31) is the following:
The expression of plasma water bicarbonate concentration at filter inlet (rearrangement of Equation 28) becomes:
Merging equations 42 and 43 provides the following expression for steady state patient bicarbonate:
The expression of bicarbonate losses to effluent (from equations 17 and 26):
J
HCO3_eff
=J
HCO3_inf
−J
HCO3
=J
HCO3_inf
+J
met_cit
−J
H+
—J
buffer_load (Eq. 44)
The relation between chosen/set nNBL0 b and JBuffer_load is as follows:
J
buffer_load
=nNBL0×BW (Eq. 45)
Therefore, equation 44 may be expressed as follows:
J
HCO3_eff
=J
HCO3_inf
+J
met_cit
−J
H+
−nNBL0×BW (Eq. 44′)
Jbuffer_load from equation 45, JH+ from equation 38, Jmet_cit from equation 37 and equation 25 or 25′ and JHCO3_inf from equation 27 are input to equation 44; the latter is then combined with equation 43 so that all terms of the this combined expression are known. CpwHCO3_inlet is finally introduced in equation 42 to derive an expression of variables defining the value of steady state patient bicarbonate which is the parameter to be set by the medical staff, which influences almost all fluid flow rates to be set.
As apparent, this solution provides an alternative parameter, namely the steady state patient bicarbonate concentration (which is again a parameter indicative of the steady state acid-base balance in the blood of the patient who has to undergo to a CRRT blood treatment), with respect to the normalized buffer load parameter, allowing medical staff to set a proper value and the control unit 12 to maintain a proper acid-base balance during the CRRT treatment.
Therapy configuration parameters are user settings that can be set in the system as to configure the CRRT modality according to local protocols and/or some customer preferences. Though it is possible to set the therapy configuration parameters any time it is needed, these user settings are generally set once for all at a certain customer place and then used for all treated patients.
Other default therapy configuration parameters may come from the system technic constraints and/or manufacturer choices. These constraints are embedded in the system and not user selectable. Examples of such parameters are flow operating ranges of the fluid circuits (e.g. calcium infusion in RCA), or mandatory relations between specific flow rates related to safety or technical considerations (e.g. maximum PBP or citrate flow rate versus blood flow rate.
The treatment configuration parameters are variables specific of the patient to be treated and of the composition of prescribed fluids (which are also part of the medical prescription).
Notably, hematocrit may alternatively be directly measured by the apparatus and on-line monitored.
Multiple default treatment configuration parameters may come together from the filter type, such as flow operating ranges and/or mass transfer coefficient(s). These are not user selectable and originate from the manufacturer. Of course, instead of providing the filter type to the apparatus (either by reading With a reader a filtration unit code or by inputting/selecting onto the user interface the used filtration unit), the relevant parameter values may be manually entered. As apparent from the following description, in the simplest approaches where clearance of small solutes is estimated identical to effluent flow rate, identification of the filter is not required. This type of approach becomes inaccurate in the scenario where dialysate and blood flow become similar, like in pediatrics application or high volume CRRT.
Operating parameters are the CRRT monitor treatment parameters computed by the assisted prescription algorithm (here below illustrated) as a function of
All the operating parameters are flow rates. The list of operating parameters is dependent on the anticoagulation method, as well as on the CRRT system capabilities and configuration.
In certain embodiments, calcium infusion may not be directly controlled by the CRRT system during RCA and infusion may be performed by a separate infusion pump. In this situation, the calculated prescribed value should be input in the external ion balancing infusion pump 75 and the control unit 12 may not verify or insure assisted prescription compliance. The same applies to anticoagulant infusion during systemic anticoagulation (usually a syringe boluses infusion).
The CRRT system may have a variable number of pumps available for fluid infusion at different locations along the extracorporeal blood circuit. See the examples of
The following table identifies operating parameters (associated to respective pumps) which will be considered in the examples. While this list refers to a maximum of 7 pumps (including the blood pump), systems including more pumps and infusion lines could be considered as well.
PBP and citrate flow rates are both indicated in the table, although they are typically delivered by the same pump in alternative configurations. PBP flow rate is specific of therapies not using citrate anticoagulation. Note that embodiment of
Assisted Prescription with No/Systemic Anticoagulation
In the context of systemic anticoagulation, a concentrated anticoagulant solution is infused in the extracorporeal blood circuit. While this prescription is clinically important, heparin infusion is not particularly relevant with respect to the CRRT prescription and calculation of flow rates since (heparin) infusion flow rate is very low, typically less than 5 ml/h matching with about 0.1% of all the fluid infusion rates, thus not impacting CRRT dosage measurably, and used anticoagulant does not interfere with acid-base equilibrium. Due to these characteristics, anticoagulation prescription in systemic anticoagulation during RRT can be seen as fully independent from the RRT prescription in itself and will not be treated in the next section which can thus address simultaneously all prescriptions using no or systemic anticoagulation.
When no or systemic anticoagulation is used, the CRRT prescription can be built from the following:
Anticoagulant prescription could be listed as well in the case of systemic anticoagulation; it however does not interfere measurably with any of the other prescription parameters and can be addressed independently.
In a system with 3 fluid infusion pumps and one effluent pump, 4 fluid flow rates are to be defined from the above 3 first prescription parameters. There is thus one degree of freedom, which may allow to consider one additional setting from the therapy configuration in the definition of operating flow rate parameters. If one additional infusion pump is added, then two degrees of freedom are available and two further settings might be selected to allow the control unit to propose corresponding flow rates matching prescription and settings. With one infusion pump less, the 3 first prescription parameter are sufficient to define the fluid flow rates for the therapy configuration.
Next table provides an indication for the interdependence between operating and prescription parameters in no or systemic anticoagulation; notably, this dependence is conditional to the definition given to/selection of the CRRT dose.
The control unit 12 is connected to the various sensors, to the actuators for regulating the flow rate through the various lines (in the above examples these actuators comprise the pumps active on the lines and the switch valves) and to the user interface. The control unit 12 may comprise a digital processor (CPU) and necessary memory (or memories) such as memory 16, an analogical type circuit, or a combination thereof. In the course of the present description it is indicated that the control unit is “configured” or “programmed” to execute certain steps: this may be achieved in practice by any means which allow configuring or programming the control unit. For instance, in case of a control unit comprising one or more CPUs, a program may be stored in an appropriate memory containing instructions which, when executed by the control unit, cause the control unit to execute the steps herein described. Alternatively, if the control unit is of an analogical type, then the circuitry of the control unit may be designed to include circuitry configured in use to execute the steps herein disclosed. The steps in the method aspects are generally performed by the control unit unless differently indicated by the circumstances.
In the examples of
This flow-rate setup procedure comprises to initially set (or accept or maintain) the therapy configuration. Indeed, the control unit 12 is configured to allow the user to select one or more therapy configurations. Therapy configurations available are exemplificatively disclosed in the previous paragraph of the present description. The CRRT dialysis dose is to be selected among the described (or additional) possibilities. For example, CRRT dose as effluent dose Dw may be selected; alternatively, urea dose Durea or any different dose type may be selected. The acid base balance parameter is selected to, e.g., between (normalized) net buffer load (n)NBL or patient systemic bicarbonate plasma concentration. Blood flow rate may be decided as prescription parameter or as operating parameter. Finally, depending on the number of degrees of freedom (namely on the number of flow rates to be set by the control unit 12 minus the prescription parameters), none, one, two or more of a convection-diffusion relation, blood pre-dilution relation and pre-post relation may be selected as additional constraints (see step 100 in
After setting/accepting the therapy configuration, the necessary treatment configuration is to be provided. See step 101 in
After the above steps, the apparatus is ready for receiving the prescription parameters, whose values are entered by the operator (see step 102 in
In case the imposed conditions are conflicting, namely there is no solution to the flow rate system given the therapy and treatment configurations, the imposed and existing constraints and the prescription parameters, an alert to the user is provided. Possibly, one or more solutions in terms of proposed operating flow rates close to the imposed conditions are provided to the user via the user interface. For example, the further mathematical relations (convection-diffusion relation, blood pre-dilution relation and pre-post relation) are given lower priority with respect to other main mathematical relations linking the input prescription parameters. A rank may also be imposed to said convection-diffusion relation, blood pre-dilution relation and pre-post relation. Alternatively, in case blood flow rate is selected as prescription parameter, the blood flow is moved to operating parameter and its value is calculated, rather than received. In other terms, the control unit 12 may be configured to manage conflicting situations with different protocols of intervention. Optionally, more than one set of solutions for the operating flow rates is provided for the user selection. Moving to the example of
The control unit 12 allows the user, e.g. through user interface 12, to select one of said relations and then may calculate the set values of all flow rates QPBP, Qrep.post, Qeff, and Qdial (step 103 in
In case a syrnge pump is also present/considered for injecting an auxiliary fluid, e.g. heparin, in the blood withdrawal line, then the above equation may be modified accordingly to account for the syringe flow rate.
Note that preset values for each one of said first, second and third ratios R1, R2, R3 may be pre-stored in the memory or that the control unit may allow entry by an operator of a set value or a set range for each one of said first, second and third ratios R1, R2, R3, e.g. via the user interface 12.
In one alternative, the memory 16 of the apparatus of
For instance, optimization criteria stored in memory 16 may comprise a first optimization criterion imposing that an emptying time of at least one among the containers of fresh fluid 14, 64, 10, 11 and/or a filling time of the waste container 62 is substantially same as, or multiple of, or proportional to the emptying time of one or more of the other containers of fresh fluid. A second optimization criterion stored in the memory 16 may impose that fluid consumption through the fluid lines is minimized. A third optimization criterion stored in memory 16 may impose that a life time of filtration unit 2 is maximized. A fourth optimization criterion stored in the memory 16 may impose that urea clearance or dialysance of a given solute is maximized.
In practice, if optimization criteria are stored in memory 16, the control unit 12 may be configured to allow the user to select (step 100), e.g. via the user interface 12, the criteria he wants to have satisfied and may be further configured to calculate the set values for the relevant operating flow rates based on the mathematical relations previously discussed that links the steady state acid-base balance parameters to the various flow rates and the selected optimization criteria and on the above mentioned fluid balance equation (FBE).
In case the selected mathematical relations (and eventually the selected criteria) are compatible, then the set flow rates are calculated based on the selected mathematical relations (and eventually optimization criteria). On the other hand, in case selected mathematical relations (and/or the selected criteria) are conflicting, the control unit 12 may be configured to execute one or more of the following sub-steps:
In accordance with a variant, the control unit may use the flow-rate setup procedure to initially calculate the flow rates set values through the various lines and during a first interval in the treatment control the actuators for regulating using said calculated set values. Then, after a certain time interval or upon detection of a user input, the control unit may recalculate the set values for the flow rates through the various lines exclusively based on one or more different prescription value and/or differently selected (or modified in value) further mathematical relation and, apply the newly calculated set values during a second time period subsequent to the first time period. For instance the flow-rate setup procedure may allow setting of the flow rates such that a certain delivered dose is attained. On the other hand, if at a certain point the user wants to privilege bag-emptying synchronization he may select to impose the first optimization criteria so that the control unit may recalculate the set values of the flow-rates allowing to synchronize as possible the emptying of the fluid bags.
The configuration of
In the present section, some examples are provided to better explain working of the CRRT apparatus.
In the context of CRRT with no or systemic anticoagulation, the possibility to adust the steady state acid-base balance equilibrium when using fluids having all similar bicarbonate content appears limited. Some possibilities exist when using simultaneously one fluid with low bicarbonate content (e.g. below 25 mM) and one with a higher content (e.g. higher than 40 mM).
Reference is made to the apparatus as shown in
Next examples S1-S5 (S stands for systemic anticoagulation or no anticoagulation) are based on the above circuit configuration and on
Effluent dose is selected as CRRT dose, therefore blood predilution does not influence dose and equations are simpler to solve. In this context of simple approach, filter clearance of small solutes pike bicarbonate) is taken equal to effluent flow rate as well; consequently no information is required on the filter type/performances.
Further, steady state bicarbonate is selected as the acid-base balance prescription parameter (when selecting steady state bicarbonate, the apparatus control unit assumes that nNBL0 is equal to 0.1 mmol/h/kg); blood flow rate is also selected among prescription parameters (reducing the degrees of freedom of the configuration). Five pumps are available and four prescription values entered. Therefore, the system has one degree of freedom and one therapy configuration constrain may be further selected to obtain a calculation of all operating flow rate parameters.
Among therapy configurations, any of convection/diffusion split, predilution ratio and pre/post infusion ratio may be selected. Predefined (modifiable) values for these relations are also included in the memory and presented to the user. Further, necessary treatment configuration values are also entered by the operator or acquired by the control unit 12.
It is assumed that the following prescription is entered by the user via user interface 12:
There are a number of additional constrains stored in the in memory 16, particularly in terms of min/max flow rates; for example: dialysate flow rate (Qdial): 0 to 6000 ml/h and replacement flow rate (Qrep.post): 0 to 4000 ml/h.
The operator selects (or has previously configured):
The control unit 12 then computes the operating parameters, namely the various flow rates as follows:
In particular:
Effluent flow rate is determined from the CRRT dialysis dose and body weight as follows: Qeff=28×75=2100 ml/h,
R
1
=Q
dial/(Qrep.post+QPBP)=1.0
Q
dial
+Q
PBP
+Q
rep.post
+Q
PFR
=Q
eff=2100
With the above two equations, Qdial can be directly calculated and set to 990 ml/h; further QPBP+Qrep.post is equal to 990 ml/h.
QPBP is then—arbitrarily—chosen as the remaining unknown parameter to compute in the next steps.
Qfil is calculated based on Eq. 8 that relates it to PBP flow rate, post-dilution flow rate and patient fluid removal rate:
Q
fil
=Q
PBP
+Q
rep.post
+Q
PFR=990+120=1110 ml/h
Then, patient steady state bicarbonate concentration (CpwHC03
All the terms of above two equations can be either computed or expressed as a function of QPBP, as shown below.
Qbw and Qbw_inlet are determined using Eq. 6 and Eq. 7:
Qbw=Q
b·[(1−Hct)·Fp+Hct·Frbc]=200·[(1−0.32)·0.95+0.32·0.85]·60=11016 ml/h
Qbw
inlet
=Q
bw
+Q
PBP=11016+QPBP
JHCO3_eff is determined based on Eq. 44:
J
HCO3_eff
=J
HCO3_inf
−J
HCO3
=J
HCO3_inf
−J
buffer_load
Jbuffer_load is determined based on Eq. 45 (with assumed nNBL0=0.1):
J
buffer_load
=nNBL0×BW=7.5 mmol/h
JHCO3_inf is determined based on Eq. 27, referencing JHCO3_inf in mmol/h and QPBP in m/h:
With the above expressions of bicarbonate rates, following expression of plasma water concentration of bicarbonate at filter inlet can be derived:
Expression of steady state patient plasma bicarbonate thus becomes:
One single solution to above equation is positive and matches with the expected PBP flow rate:
Post-replacement flow rate is then easily derived as:
Q
rep.post=990−QPBP=768 ml/h
The flow rate values are finally rounded.
Similarly to previous example S1, effluent dose is selected as CRRT dose (blood predilution does not influence dose), filter clearance of small solutes (like bicarbonate) is considered equal to effluent flow rate, too.
Vice versa, normalized net buffer load nNBL is selected as acid-base balance prescription (when nNBL, the apparatus control unit assumes that CpHCO3_pat0 is equal to 25 mM); blood flow rate is also selected among prescription parameters (reducing the degrees of freedom of the configuration). As in the previous example, five pumps are available and four prescription values are entered. Therefore, the system has one degree of freedom and one therapy configuration constrain may be further selected to obtain a calculation of all operating flow rate parameters.
Among therapy configurations, any of convection/diffusion split, predilution ratio and pre/post infusion ratio may be selected. Predefined (modifiable) values for these relations are also included in the memory and presented to the user. Further, necessary treatment configuration values are also entered by the operator or acquired by the control unit 12. Changed values are identified with different background shading.
Note that acid-base balance prescription is switched to nNBL and solutions with low and high bicarbonate concentrations are used to provide for some possibilities of adjustment of acid-base balance.
It is assumed that the following prescription is entered by the user via user interface 12:
This time, the operator selects:
The control unit 12 then computes the operating parameters, namely the various flow rates as follows:
In particular:
Effluent flow rate is determined as follows: Qeff=28×75=2100 ml/h,
R
2
=Q
PBP
/Q
rep.post=0.5
Q
dial
+Q
PBP
+p
rep.post
+Q
PFR
=Q
eff=2100
Then, normalized net buffer balance (nNBL) is defined on the following mathematical relations, namely Eq. 41, Eq. 26, Eq. 27, Eq. 28, which relates the various flow rates generating a further fluid flow rate constrain (the terms relating to missing fluid lines have been removed from the relevant equations):
According to assumption KHCO3 is approximated with the effluent flow rate (see Eq. 30):
J
HCO3_bal
=Q
rep.post
·C
HCO3
+Q
PBP
·C
HCO3
−[Q
eff·(CpwHCO3
Qfil is calculated based on Eq. 8:
Q
fil
=Q
PBP
+Q
rep.post
+Q
PFR
CpwHCO3
Qbw and Qbw_inlet are determined using Eq. 6 and Eq. 7:
Qbw=[Q
b·(1−Hct)·Fp+Hct·Frbc]
Qbw
inlet
=Q
bw
+Q
PBP
=Q
b·[(1−Hct)·Fp+Hct·Frbc]+QPBP
Leading to Qdial=600 ml/h, Qrep.post=920 ml/h, QPBP=460 ml/h
Similarly to previous example S2, effluent dose is selected as CRRT dose, filter clearance of small solutes (like bicarbonate) is considered equal to effluent flow rate, normalized net buffer load nNBL is selected as acid-base balance prescription (when nNBL, the apparatus control unit assumes that CpHCO3_pat is equal to 25 mM), too.
Vice versa, blood flow rate is removed from prescription parameters (increasing the degrees of freedom of the configuration). Now, five pumps are available and three prescription values are entered. Therefore, the system has two degrees of freedom and two therapy configuration constrains may be further selected to obtain a calculation of all operating flow rate parameters.
Among therapy configurations, any of convection/diffusion split, predilution ratio and pr/post infusion ratio may be selected. Predefined (modifiable) values for these relations are also included in the memory and presented to the user. Further, necessary treatment configuration values are also entered by the operator or acquired by the control unit 12. Changed values are identified with different background shading.
Note that acid-base balance prescription is switched to nNBL and solutions with low and high bicarbonate concentrations are used to provide for some possibilities of adjustment of acid-base balance.
It is assumed that the following prescription is entered by the user via user interface 12:
The operator selects:
Since Qb is an operating parameter to be calculated, the convection diffusion further mathematical relation is added to the previous equations/mathematical relations used for example S2.
The control unit 12 then tries to compute the operating parameters, namely the various flow rates. The additional degree of freedom provided by the blood flow setting left to the control unit calculation allows to select the additional equation imposing the pre/post infusion ratio. The other used equations are the same used for the previous example S2; however, in the present case, the equation system has no solution with the imposed settings.
In examples S1 and S2, it is possible to find operating parameters exactly matching with all prescription parameters, as well as to the CRRT flow configuration constraint. In the example S3, with one additional degree of freedom (blood flow), it is not possible to meet all the prescription parameters simultaneously to the two CRRT flow configuration constraints; in this case, the system should choose one out of the two flow configuration constraints (possibly from a predefined prioritization ranking) as to offer for operating flow rates meeting all prescription parameters, but the second constraint.
In the same example S3, once considering only one of the two therapy flow configuration constraints, multiple solutions exist. The system can either report the solution which is the closest to the ‘dropped’ flow constraint (in example S3, the set of parameters with Qb=100 ml/min, wherein the convection diffusion split is 66%-34% instead of 67%-33%), or to offer several options to the operator. In the example, operating parameters with one larger blood flow rate (Qb=200 ml/min) is suggested in addition to the closest solution.
Next examples S4 and S5 include the same system configuration as in previous series of examples is considered; moreover, examples S4 and S5 are identical to examples S1 and S2 except for the chosen definition of CRRT dose; in below examples S4 and S5, CRRT dose refers to urea clearance, and thus considers the effect of predilution.
In this context, more complex equations are used for the estimation of the clearances of urea (CRRT dose—see Eq. 12) and bicarbonate (acid-base balance analysis); mass transfer properties (K0.A) of the filter must be known.
This example is identical to example S1, but for the chosen definition of CRRT dose.
With the above prescription data and selected constrain, the control unit may propose to the user the following operating flow rate parameters:
This example is identical to example S2, but for the chosen definition of CRRT dose.
With the above prescription data and selected constrain, the control unit may propose to the user the following operating flowrate parameters:
K0.A parameter relates to the type of CRRT filter in use and specifies the diffusive mass transfer performance for bicarbonate or urea, which are assumed to be identical in these examples; the assumption relies of the similar molecular weight to the 2 species (60 g/mole for urea, 61 g/mole for HCO3−).
As expected with the use of a CRRT dose integrating the effect of predilution, higher effluent flow rates are computed in examples S4 and S5 when compared to examples S1 and S2.
Assisted Prescription with Citrate Anticoagulation
In the context of citrate anticoagulation and as previously described, a citrate solution is infused in the access line of the extracorporeal circuit, particularly next to the patient vascular access, upstream from the blood pump. Simultaneously, a calcium solution for re-establishing the ion content in the blood is infused directly into the patient or into the return line of the circuit as to balance calcium (and possibly other ions) losses to effluent.
Flow rates of the two infusions relate to the anticoagulation prescription (amount of citrate titrated to reach a certain level of ionised calcium in the extracorporeal blood circuit) and CRRT dose prescription (for the calcium losses), as well as to the concentrations of the respective citrate and calcium solutions.
Even in the context of ‘concentrated’ solutions (e.g. 110-140 mM of citrate, >500 mM calcium), the combined flow rate of citrate and calcium infusions has a measurable contribution to the CRRT dose (in the 5 to 10% range).
In addition, a fraction of infused citrate returns to the patient and is metabolized, leading to the release of calcium and production of bicarbonate impacting on the acid-base balance equilibrium.
Accordingly, at the opposite of systemic anticoagulation, citrate anticoagulation prescription has complex interactions with both CRRT dose and acid-base balance management. These interactions introduce significant level of complexity in the prescription of CRRT with citrate anticoagulation.
When citrate anticoagulation is used, the CRRT patient prescription may be built from following clinical prescription parameters, all of which have a clear meaning for the medical staff dealing with CRRT treatments):
In a system with 4 fluid pumps (dialysis+infusion pumps) and one effluent pump, 5 fluid flow rates are to be defined from the above 5 first prescription parameters. There is thus no degree of freedom left, and no option to consider additional setting from the therapy configuration (unless defining blood flow as operating parameter).
Next table provides for the interdependence between operating and prescription parameters; importantly this dependence can be conditional to the definition given to the CRRT dose.
Although simplified expressions may be considered, the complexity of interactions between the mass transfer of citrate complexes and bicarbonate in the CRRT filter justifies the use of more accurate estimates of filter clearance, requiring access to the mass transfer properties of the filter in use. In this context, all examples will include these parameters. Examples will illustrate use of ‘concentrated’ or ‘diluted’ citrate solutions, as commonly used in the clinical practice.
In all the following examples, calcium concentration of the citrate and dialysate solutions is assumed to be zero. Presence of calcium in the post-infusion fluid will be considered in some examples.
All flow rates are rounded to the next ten, except when less than 100 ml/h.
The system configuration used throughout the next examples is comparable to the system configuration considered in examples S1 to S5, but for the addition of one pump for calcium infusion. Of course the pre-blood-pump infusion line infuses citrate, rather than a replacement solution as in previous examples S1 to S5. Though the pre-blood-pump infusion line can be physically the same used in the previous examples (see
CRRT system definition for the examples C1 to C6 is indicated in the following table.
Next examples C1 to C5 are based on the above circuit configuration and on
In this first series of examples, CRRT dose is referred to effluent rate without correction for predilution.
Parameters changed in the consecutive examples of this section are identified in coloured cells.
The first reference example is built using normalized Net Buffer Load as acid-base balance prescription use of diluted citrate solution and blood flow rate as clinical prescription parameters.
Therapy configuration is set as per the following table. Treatment configuration data are requested and entered according to the second table below reported.
As indicated the following clinical prescription parameters are input by the medical staff:
Since the prescription parameter provides for 6 constraints, there is no degree of freedom available to further set additional therapy configurations.
With the above apparatus set, the control unit determines the following operating flow rates (Qb is indicated, but it is a prescription parameter already set to 130 ml/min).
In particular, effluent flow rate Qeff is determined based on CRRT dose and patient weight:
Q
eff=30.85=2550 ml/h
Anticoagulant flow rate Qcit is related to blood flow rate by the citrate flow rate mathematical relation (Eq. 1):
Since blood flow rate Qb and citrate dose Dcit are imposed and citrate concentration is known, Qcit is immediately derived from above equation.
Calcium flow rate derives from calcium flow rate mathematical relation (Eq. 2); missing flow rates and terms equal to zero, or negligible have been removed from the general formulation of the description:
As indicated in the previous examples, the effluent flow rate should respect the fluid balance (see equation 10):
Q
eff
=Q
cit
+Q
dial
+Q
rep.post
+Q
PFR
+Q
ca
The last but more complex constraint is based on the normalized net buffer load parameter target nNBL due to its interaction with all flow rates and effects of buffer balance from bicarbonate and bicarbonate precursors, i.e., citrate. Net buffer load mathematical relations links the parameter with the citrate load and bicarbonate balance (Eq. 40 and Eq. 41):
The citrate load is determined based on citrate load mathematical relation (Eq. 25) that takes into account for citrate metabolic clearance:
Citrate clearance Kcit derives from Eq. 21 (with SCcit=1):
Wherein the plasma water flow rate Qpwinlet at the filtration unit inlet comes from Eq. 5:
Qpw
inlet
=Q
b·(1−Hct)·Fp+Qcit
And plasma water flow rate Qpw is calculated from Eq. 4:
Qpw=Q
b·(1−Hct)·Fp
Ultrafiltration flow rate through the filtration unit 2 is (Eq. 8):
Q
fil
=Q
cit
+Q
rep.post
+Q
PFR
+Q
ca
Metabolic clearance for citrate is estimated with Eq. 22:
Vice versa, second term of the net buffer load, namely the bicarbonate balance JHCO3_bal, comes from e.g., Eq. 26′:
J
HCO3_bal
=Q
rep.post
·C
HCO3rep.post
−K
HCO3·(CpwHCO3
Bicarbonate clearance is more precisely estimated through bicarbonate clearance mathematical relations (Eq. 29); SCHCO3=1:
Blood water flow rate Qbwinlet at filtration unit inlet comes from Eq. 7:
Qbw
inlet
=Q
b·[(1−Hct)·Fp+Hct·Frbc]+Qcit
Blood water flow rate is derived from Eq. 6:
Qbw=Q
b[(1−Hct)·Fp+Hct·Frbc]
Finally, required plasma water bicarbonate concentration CpwHCO3_inlet at filter inlet from Eq. 32 is:
Wherein bicarbonate concentration in the patient plasma at steady state is fixed and assumed constant (e.g., 25 mM). Using all the above mathematical relations, the control unit 12 determines all the operative prescription parameters.
Second example is using previous example C1 as reference and illustrates the changes in flow rates required further to a change of citrate dose prescription, which could be required to keep blood circuit ionized calcium within recommended levels (e.g. in the 0.25-0.35 mM range).
Therapy configuration is set as per the following table. Treatment configuration data are requested and entered according to the second table below reported.
Since the prescription parameter provides for 6 constraints, there is no degree of freedom available to further set additional therapy configurations.
With the above apparatus set, the control unit determines the following operating flow rates (Qb is indicated, but itis a prescription parameter already set to 130 ml/min). As can be seen, ail operating flow rates are significantly affected by the citrate dose change, but the effluent flow rate.
In the continuation of the two previous examples, example C3 illustrates changes required further to an increase of citrate dose.
Therapy configuration is set as per the following table. Treatment configuration data are requested and entered according to the second table below reported.
Since the prescription parameter provides for 6 constraints, there is no degree of freedom available to further set additional therapy configurations.
With the above apparatus set, the control unit tries to determine the operating flow rates (in the second column, Qb is indicated, but it is a prescription parameter already set to 130 ml/min). As can be seen, there is no solution to the equation system compatible with the prescription.
All operating flow rates are significantly affected by the citrate dose change, but the effluent flow rate and it is not possible to achieve the desired targets. Third column provides a proposed solution considering Qb as an operating parameter (that may vary within prescribes limit values).
The example C4 is based on C1 reference with the replacement of the diluted citrate solution with a ‘concentrated’ one; calcium solution is changed as well with a less concentrated one.
Highlighted changes are those in reference to C1 example.
Therapy configuration is set as per the following table. Treatment configuration data are requested and entered according to the second table below reported.
Since the prescription parameter provides for 6 constraints, there is no degree of freedom available to further set additional therapy configurations.
With the above apparatus set, the control unit tries to determine the operating flow rates (in the second column, Qb is indicated, but it is a prescription parameter already set to 130 ml/min). As can be seen, there is no solution to the equation system compatible with the prescription.
All operating flow rates are significantly affected by the citrate dose change, but the effluent flow rate and it is not possible to achieve the desired targets Third column provides a proposed solution considering Qb as an operating parameter (that may vary within prescribes limit values).
Above examples C1 to C4 illustrates the importance of blood flow rate during citrate anticoagulation for the definition of adequate acid-base balance when having fixed bicarbonate composition of the fluids.
Similarly to the series of example provided in no or systemic anticoagulation, next examples are provided in the context of RCA, where CRRT dose includes a factor for predilution, for example where referring to Urea clearance dose.
Same system configuration is the same used for examples C1 to C4 (see
This example is built in reference to example C1, replacing effluent CRRT dose with urea clearance dose (see relevant paragraph). Changes are highlighted in reference to example C1.
Therapy configuration is set as per the following table. Treatment configuration data are requested and entered according to the second table below reported.
Since the prescription parameter provides for 6 constraints, there is no degree of freedom available to further set additional therapy configurations.
With the above apparatus set, the control unit determines the following operating flow rates (Qb is indicated, but itis a prescription parameter already set to 130 ml/min).
Similar simulation as done between examples C2 and C1 is repeated here between C6 and C5.
Changes between C6 and C5 are those highlighted in next table.
Therapy configuration is set as per the following table. Treatment configuration data are requested and entered according to the second table below reported.
Since the prescription parameter provides for 6 constraints there is no degree of freedom available to further set additional therapy configurations.
With the above apparatus set, the control unit determines the following operating flow rates (Qb is indicated, but itis a prescription parameter already set to 130 ml/min).
Examples C5 and C6 shows the major impact of blood predilution when using ‘diluted’ citrate solutions and referring to a CRRT dose integrating the impact of predilution, like urea clearance dose. Effluent flow rate is significantly increased between examples C5-C6 and C1-C2 (about 400 to 500 ml/h).
In parallel, these examples show the major adjustments of dialysate and post-replacement flow rates required to maintain the desired acid-base balance while increasing the CRRT dose.
This section provides for assisted prescription examples in the context of a system where a concentrated bicarbonate solution is infused post filter and contributes to a major part of all bicarbonate infused through the CRRT therapy (via all fluids including dialysate). Ideally, this major part is more than 50% and may reached 100%; in the latter case, this means that all fluids are bicarbonate free, except the concentrated bicarbonate infusion.
Purpose of the system configuration is to decouple as much as possible acid-base balance prescription from CRRT dose and/or citrate dose prescriptions, providing thus for more freedom in varying these parameters independently. All examples provided in this section are built using a CRRT dose based on urea clearance, and thus factoring the impact of predilution.
The system configuration used throughout the next examples is comparable to the system configuration considered in examples S1 to S5 for the number of fluid pumps (n=4) and the presence of one infusion circuit in pre-dilution and one in post-dilution; it however includes several changes as reported in next table.
The CRRT system definition referred to examples BS1 to BS2 (BS stands for bicarbonate+systemic or no anticoagulation) is shown in the following table and also shown in
This example is comparable to example S5, but for the composition of fluids and the therapy configuration parameter. Therapy configuration is set as per the following table. Treatment configuration data are requested and entered according to the second table below reported.
Since one degree of freedom is available, one additional constraint may be selected, in the present example, convection diffusion split (or ratio) is selected and set to 50%-50% or R1=1.
Given the above clinical prescription parameters and the additional user selection of therapy configuration, the control unit 12 determines the following operating parameters (Qb being part of the prescription):
This example is comparable to previous and targets a much higher net buffer load. Changes from previous example BS1 are highlighted with backgrounded calls.
Therapy configuration is set as per the following table. Treatment configuration data are requested and entered according to the second table below reported.
The clinical prescription parameters are the same as in the previous example BS1, but the nNBL is changed from 0.15 to a sensibly higher 0.25 value.
The calculated flow rates for the remaining operating parameters are as follows (Qb being still part of the prescription):
In the context of a system having only bicarbonate infusion as post-infusion, it is not relevant/possible to include therapy parameters such pre-post infusion ratio, as the post infusion rate is dictated by the acid-base balance prescription. In other terms, selection of pre-post infusion ratio would have caused the control unit to return no solution to the equation system. Therefore, selection of convection/diffusion ratio appears to be the exclusively reasonable selection among therapy additional constraints.
Comparison of examples BS1 and BS2 illustrates the strong and direct dependence of acid-base balance equilibrium on the bicarbonate post infusion flow rate, in a configuration where more than 80% of total bicarbonate infusion comes from a single source.
Notably, the ‘high’ nNBL level prescription of example BS2 cannot be provided in the conventional system and bicarbonate fluid configurations of examples S4-S5, unless using extremely high CRRT prescribed dialysis dose (e.g. about 50 ml/kg/h).
The concept of bicarbonate infusion is further illustrated in the context of citrate anticoagulation (RCA).
Selected system configuration is comparable to the configuration of examples C1-C6 with the addition of a bicarbonate post-infusion pump. This system is thus including six fluid pumps and one blood pump (see the example of
See
This example is similar to previous example C5, but for the addition of the bicarbonate post infusion and the use of buffer-free dialysate.
Therapy configuration is set as per the following table. Treatment configuration data are requested and entered according to the second table below reported.
As below indicated, Qb is still a prescription parameter in addition to the prescribed dialysis dose (Dset—urea clearance) to be delivered, to the normalized net buffer load, to the patient fluid removal rate (QPPF) and the RCA prescriptions:
There is one remaining degree of freedom based on the six prescription parameters and the seven flow rates to be determined. However, the selected convection-diffusion split cannot be reached given the system configuration and the clinical prescription parameters:
The control unit 12 provides for the solution relating to flow rates for the operating parameter which is closest to the convection diffusion ratio selected. In the present case the convection diffusion ratio is 57%-43% r (R1=1.33). As an alternative, Qb is moved from prescription parameter to operating parameter and the convection diffusion ratio is kept at 50%-50% as originally set Resulting blood flow rate is reduced to 100 ml/min.
BC2 example is similar to BC1 with a change of the citrate solution towards a higheron centration. Changes from BC1 are highlighted.
Therapy configuration is set as per the following table. Treatment configuration data are requested and entered according to the second table below reported.
Clinical prescription parameters are unaltered with respect to example BC1:
With the change (increase) in anticoagulant bag concentration for citrate, the control unit 12 finds a solution for the operating flowrates without the need to change the set blood flow rate and/or changing the convection diffusion split:
BC3 illustrates the changes in flow rates when changing citrate dose prescription given in example BC2.
Changes from BC2 are highlighted.
Therapy configuration is set as per the following table. Treatment configuration data are requested and entered according to the second table below reported.
As below indicated, citrate dose is raised from 3.1 to 3.5 mmol/L:
The calculated operating parameters are as follows (blood flow rate being a prescription parameter):
Addition of the bicarbonate post-infusion pump adds one degree of freedom and enables to consider one therapy configuration constraint in example BC1 (when compared to C5). However use of a ‘diluted’ citrate solution drives for significant convective flow and makes difficult to achieve an HDF prescription with equal convection and diffusion flow rates.
Example BC2 documents the benefit of more concentrated citrate solution when targeting a CRRT therapy configuration with significant dialysis/diffusion contribution, further to the decrease of citrate solution flow rate (which contributes to convective fluid exchange).
Example BC3 indicates that changes in citrate dose (for the purpose of anticoagulation intensity adjustment) can be easily balanced via adjustment of the bicarbonate post-infusion rate in order to keep the same acid-base equilibrium target.
Compatibility with Other System Features
High level interactions exist between the assisted prescription feature and optional features and an advanced CRRT system.
Blood flow rate management: in the configuration where the system is equipped with a module optimising automatically the blood pump speed as a function of vascular access performance, the system should operate with blood flow defined as operating parameter, rather than prescription parameter. A maximum blood flow rate value should however be offered as an operator settable constraint. In these conditions, the control unit shall re-compute automatically the various flow settings each time the blood flow rate is adjusted by the ‘blood pump management’ module.
TMP monitoring/convection: in the configuration where the system is equipped with a module optimising automatically the convective flow rate as a function of TMP (or other pressure parameters), the assisted prescription system, namely the control unit shall re-compute automatically the various flow settings each time the convective flow rates are adjusted.
Dose Control: Assisted prescription module provides for the computation of flow rate settings, while the Dose Control system monitors the ‘instantaneous’ CRRT dose requirements along the therapy in order to achieve an overall CRRT dose clinical target over several days of treatment. The assisted prescription enhancement brought with the inclusion of acid-base balance prescription parameter makes the Dose Control system applicable to citrate anticoagulation in a safe and practical way.
Here below the main mathematical relations that the control unit 12 uses to link patient prescription parameters, treatment configuration parameters and operating parameters are reported. The mathematical relations are already described in detail in the previous sections of the present application. When the necessary and/or selected patient prescription parameters and treatment configuration parameters are received, the control unit 12 is configured to use the relevant mathematical equations to calculate the set flow rates of fluid in the lines for the operating parameters. The control unit 12 may then output the set and calculated flow rates for acceptance to a user and, after acceptance, drive the various actuators (pumps) to obtain the set and calculated flow rates in the relevant lines. Alternatively, the control unit 12 may automatically set the actuators to achieve the set and calculated flow rates.
Qp=Q
b·(1−Hct)
Qpw=Qp=·F
p
=Q
b(1−Hct)·Fp
QPw
inlet
=Qpw+Q
cit
+Q
syr
+Q
PBP
+Q
rep.pre=
Q
b·(1−Hct)·Fp+Qcit+Qsyr+QPBP+Qrep.pre
Qbw=Q
b·[(1−Hct)·Fp+Hct·Frbc]
Qbw
inlet
=Q
bw
+Q
cit
+Q
syr
+Q
PBP
+Q
rep.pre=
Q
b·[(1−Hct)·Fp+Hct·Frbc]+Qcit+Qsyr+QPBP+Qrep.pre
Q
fil
=Q
PBP
+Q
cit
+Q
syr
+Q
rep.pre
+Q
rep.post
+Q
HCO3
+Q
PFR
+Q
ca
Q
rep.pre
=PRE·Q
rep
Q
rep=(Qrep.pre+Qrep.post)
Q
eff
=Q
PBP
+Q
cit
+Q
syr
+Q
dial
+Q
rep.pre
+Q
rep.post
+Q
HCO3
+Q
PFR
+Q
ca
Eq. 12—Urea Clearance (Diffusive and/or Convective Mode)
J
buffer_load=J
+J
bal
+J
met_lact
−J
H+
J
citrate_load
=J
cit_PBP
−J
cit_dial
J
cit_PBP
=Q
cit
·C
it_PBP
=D
cit
·Q
b
J
cit_dial
=K
cit
·Cpw
cit_inlet
Eq. 25/25′—Citrate Load Mathematical Relation/s
J
HCO3_inf
=Q
dial
·C
HCO3
+Q
cit
·C
HCO3
+Q
PBP
·C
HCO3
+Q
rep.pre
·C
HCO3
+Q
rep.post·
C
HCO3
+Q
HCO3
·C
HCO3
J
HCO3_eff
=Q
dial
·C
HCO3
+K
HCO3·(CpwHCO3_inlet−CHCO3_dial)+Qfil·CHCO3_dial
J
met_cit=3·Jcit_load
J
H+=3·Jcitric_acid=3·Qcit·Ccit_PBP
Number | Date | Country | Kind |
---|---|---|---|
102020000026206 | Nov 2020 | IT | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/EP2021/080100 | 10/29/2021 | WO |